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Figure 18. Hepatocyte-specific Ascl1 ablation phenotypes in spleen and kidney. The maternal 
spleens and kidneys were collected and weighed from Ascl1fl/fl and hep-Ascl1-/- mice (described in 
Fig. 9). (A) Morphology of the Ascl1fl/fl and hep-Ascl1-/- mouse spleens on gestation day (GD) 18. 
(B) The maternal spleen-to-body weight ratios of Ascl1fl/fl and hep-Ascl1-/- mice are presented. 
Data are expressed as means ± s.d. (n = 4-10). *, P < 0.05, between Ascl1fl/fl and hep-Ascl1-/- mice. 
(C) Maternal splenic histology. Maternal splenic sections of Ascl1fl/fl and hep-Ascl1-/- mice on 
GD15 were subjected to hematoxylin and eosin (H&E) staining. (D) The maternal kidney-to-body 
weight ratios of Ascl1fl/fl and hep-Ascl1-/- mice are presented. Data are expressed as means ± s.d. 
(n = 4-5). ***, P < 0.001, between Ascl1fl/fl and hep-Ascl1-/- mice. ............................................ 104 
Figure 19. Hepatocyte-specific Ascl1 ablation phenotypes in the placenta. The maternal 
placenta was collected and weighed from Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). (A) 
Placental weights of Ascl1fl/fl and hep-Ascl1-/- mice are presented. Data are expressed as means ± 
s.d. (n = 4-9). *, P < 0.05; **, P < 0.01, between Ascl1fl/fl and hep-Ascl1-/- mice. (B-D) Maternal 
placental histology. Placental sections of Ascl1fl/fl and hep-Ascl1-/- mice on gestation day (GD) 15 
were subjected to (B) hematoxylin and eosin (H&E) and (C) periodic acid-Schiff (PAS) staining. 
The glycogen is stained red to purple. (D) Placental sections were also subjected to PL-I and PL-
II in situ hybridization staining using RNAscope 2.5 HD Assay-BROWN kit. The PL-I and PL-II 
mRNAs are stained dark brown. (E) Maternal serum analysis. Maternal serum was collected from 
Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). Maternal serum alkaline phosphatase (ALP) 
from Ascl1fl/fl and hep-Ascl1-/- mice was analyzed by Eli Lilly and Company. (F) Placental protein 
expression. Western blotting was performed on GD15 and GD18 placental homogenates from 
Ascl1fl/fl and hep-Ascl1-/- mice using antibodies against the proteins listed. GAPDH protein levels 
were used as loading controls. (G) Quantification of the placental protein expression. Placental 
protein levels from Fig. 19F were measured using ImageJ and expressed as the mean fold changes 
relative to GD15 controls (± s.d.; n = 3 for each group). *, P < 0.05, between Ascl1fl/fl and hep-
Ascl1-/- mice. Ascl1, achaete-scute homolog 1; IGF2, insulin-like growth factor; ERK1/2, 
extracellular signal-regulated kinase 1/2; JAK2, Janus kinase 2; PL-II, placental lactogen II; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase. .............................................................. 106 
Figure 20. Hepatocyte-specific Ascl1 ablation phenotypes in the fetus and postnatal growth. 
Fetuses and weaned pups were collected and weighed from Ascl1fl/fl and hep-Ascl1-/- dams 
(described in Fig. 9). Fetal weight (A) and numbers (B) were recorded. (C-F) Postnatal pups were 
weighed after weaning. (G) Fetal glucose measurement. Fetal blood glucose was measured using 
a glucometer (OneTouch Ultra 2) 5 weeks after weaning. (± SEM; n = 13-31). *, P < 0.05; **, P 
< 0.01; ***, P < 0.001, between pups born from Ascl1fl/fl and hep-Ascl1-/- dams. Ascl1, achaete-
scute homolog 1. ......................................................................................................................... 113 
Figure 21. Hepatocyte-specific Ascl1 ablation phenotypes in maternal cecal microbiota. The 
maternal cecal samples were collected from Ascl1fl/fl and hep-Ascl1-/- mice on gestation day (GD) 
18 (described in Fig. 9). (A) DNA was isolated from maternal cecal microbiota of Ascl1fl/fl and 
hep-Ascl1-/- mice on GD18 using the PureLink Microbiome DNA Purification Kit. Maternal cecal 




isolated from livers of nonpregnant (NP) and pregnant (GD15 and GD18) Ascl1fl/fl and hep-Ascl1-
/- mice. Hepatic hepcidin antimicrobial peptide 2 (Hamp2) mRNA levels were measured using 
quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as the mean fold 
changes relative to nonpregnant (NP) controls (± s.d.; n = 3-4). **, P < 0.01; ***, P < 0.001, 
between Ascl1fl/fl and hep-Ascl1-/- mice. 18S ribosomal RNA (rRNA) levels were used as 
endogenous controls. Ascl1, achaete-scute homolog 1. .............................................................. 116 
Figure 22. Summary of hepatic Ascl1 functions during pregnancy. Ascl1, achaete-scute 
homolog 1; IGF2, insulin-like growth factor 2; Hamp2, hepcidin antimicrobial peptide 2; HGF, 
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The maternal liver exhibits robust adaptations to pregnancy to accommodate the metabolic needs 
of developing and growing placenta and fetus by largely unknown mechanisms. We found that 
achaete-scute homolog 1 (Ascl1), a basic helix-loop-helix transcription factor essential for 
neuronal development, is highly activated in maternal hepatocytes during the second half of 
gestation in mice. Our aim is to investigate whether and how Ascl1 plays a pregnancy-dependent 
role. We deleted the Ascl1 gene in the maternal liver using three independent mouse models from 
mid-gestation until term and identified multiple Ascl1-dependent phenotypes. When Ascl1 was 
deficient in maternal hepatocytes, maternal livers exhibited aberrant hepatocyte histology, fat 
accumulation, increased hepatocyte cell cycle, and enlarged size, accompanied by reduced 
albumin production and elevated levels of free fatty acids, ALT, and AST in the maternal blood, 
indicating maternal liver dysfunction. In the same situation, maternal spleen and pancreas 
displayed marked enlargement without an overt structural change; the placenta exhibited striking 
overgrowth with increased ALP production; and the cecal microbiome showed alterations in the 
relative abundance of several bacterial subpopulations. Moreover, litters born from maternal 
hepatic Ascl1 null mutated dam experienced abnormal postnatal growth after weaning. RNA-seq 
analysis revealed Ascl1-regulated genes in the maternal liver associated with Ascl1-dependent 
phenotypes. Of particular interest, we found that, in maternal hepatocytes, Ascl1 loss-of-function 
caused the activation of paternally imprinted gene insulin-like growth factor 2 (Igf2) encoding a 
major placental and fetal growth factor. IGF2 is also a known mitogen for hepatocytes and several 
hematopoietic lineages. Thus, IGF2 is a potential inducer of Ascl1-dependent phenotypes 
including placental overgrowth and maternal organ enlargement. Our studies revealed Ascl1 as a 




hepatocytes is essential for normal placental growth and appropriate maternal organ adaptations, 





The liver is a vital organ that performs many essential physiological processes to maintain 
the homeostasis of the body (1). Under homeostasis, the liver maintains its liver-to-body weight 
ratio; however, this ratio can change during pathological conditions and, interestingly, during a 
physiological condition such as pregnancy. Pregnancy results in dynamic physiological changes, 
such as an enlarged maternal liver, which alters the mother’s homeostasis to accommodate the 
developing placenta and the growing fetus. However, there is scarce information regarding 
mechanisms involved in the enlargement and adaptations of the maternal liver to pregnancy. 
During pregnancy, we found that a proneural transcription factor achaete-scute homolog 1 (Ascl1), 
a mammalian achaete-scute homolog (Mash) family member and normally quiescent in the liver, 
is highly activated in the maternal liver. Therefore, we investigated the function of the maternal 
hepatic Ascl1 and its role in pregnancy.  
The introduction section provides a summary of the current knowledge of the liver during 
development, homeostasis, pregnancy, and diseases associated with pregnancy; nonreproductive 
organs during pregnancy; and the Mash family members. The materials and methods section lists 
important steps of the experiments in collecting the data. The results section presents our findings 
linking maternal hepatic Ascl1 to the adaptations of the maternal liver as well as nonreproductive 
organs and pregnancy outcomes. The discussion section summarizes the important functions of 
hepatic Ascl1 and gives novel insights into the vital role of the maternal liver in communicating 






The fetal liver develops during early embryogenesis and ends after postpartum by 
undergoing four major stages: competency, commitment, differentiation, and growth (2). During 
competency at embryonic day (E) 7 in mice, the endoderm forms and specific cells become 
committed to a hepatic lineage by expressing transcription factors such as forkhead box A (FOXA) 
1/2 and GATA binding protein (GATA) 4/6 (3, 4). The commitment stage has three phases: hepatic 
specification, liver diverticulum, and liver bud initiation. During hepatic specification at E8.5, the 
septum transversum mesenchyme (STM) expresses bone morphogenetic proteins (BMPs) and 
cardiac mesoderm expresses fibroblast growth factors (FGFs) to enable the committed cells in the 
foregut endoderm to become hepatoblasts, the progenitor cells to hepatocytes and cholangiocytes 
(5-8). During the formation of the liver diverticulum at E9, the hepatoblasts express hepatic genes 
such as albumin (ALB), α-fetoprotein (AFP), transthyretin (TTR), hepatocyte nuclear factor 4α 
(HNF4A), high expressions of cytokeratin (CK)-8/18, and low expression of CK-19 (8). During 
the liver bud initiation at E9-9.5, the hepatoblasts proliferate and migrate to the adjacent STM and 
form an embryonic liver bud (9-11). During differentiation at E10-15, the liver bud grows rapidly 
from paracrine signals such as FGF, BMP, hepatocyte growth factor (HGF), transforming growth 
factor beta (TGF-β), retinoic acid (RA), and Wnt from the STM and hepatic mesenchyme. At E14, 
the hepatoblasts differentiate into either hepatocytes or cholangiocytes. Oncostatin M (OSM), 
glucocorticoids, HGF, and Wnt promote hepatoblasts to differentiate into hepatocytes by 
expressing hepatocyte markers such as ALB, CK-8/18, hepatocyte nuclear factor (HNF) 1-4α, and 
CCAAT/enhancer-binding protein alpha (C/EBPα). On the other hand, TGF-β, Jagged-Notch, 




expressing cholangiocyte markers such as biliary cell surface antigen BDS7, CK-19, onecut [OC]-
1/2, and HNF1β (12, 13). Many signaling pathways operating during liver development reactivate 
during liver regeneration and repair in adults. 
1.1.2 Function 
The liver is the largest solid organ in the body and performs an essential role in maintaining 
the homeostasis of the body by synthesizing plasma protein and bile, metabolizing glucose, fatty 
acid, amino acid, bilirubin, and drugs, and storing glycogen (14, 15). To accomplish these vital 
functions, the liver contains heterogeneous populations of parenchymal and nonparenchymal cells. 
The parenchymal cells of the liver are hepatocytes, which make up around 80% of the total liver 
weight and nearly 70% of the total number of hepatic cells, and performs the majority of the 
biological functions of the liver such as metabolism, secretion, storage, detoxification, and 
degradation (16). The nonparenchymal cells of the liver are cholangiocytes (also known as biliary 
epithelial cells), sinusoidal endothelial cells, Kupffer cells, pit cells, and hepatic stellate cells (17). 
The cholangiocytes are the ductal cells of the liver and direct bile secreted by the hepatocytes to 
the gall bladder. The sinusoidal endothelial cells are a highly specialized fenestrated hepatic 
vasculature that allows an exchange of molecules and proteins between the blood and the 
hepatocytes. The Kupffer cells are the hepatic macrophages that scavenge for foreign materials, 
wastes, and bacteria. The pit cells are rare hepatic natural killer cells that play a role in cytotoxicity. 
The hepatic stellate cells store fat and vitamin A, and maintain the extracellular matrix; however, 
during liver injury, the hepatic stellate cells are activated to become myofibroblasts, which result 
in liver fibrosis (12). The liver, therefore, maintains the homeostasis of the body via diverse 




The liver is made up of basic functional units called the liver lobules, which are a hexagonal 
arrangement of hepatocytes, the portal triads, and the central vein connected together by the 
sinusoidal endothelial cells (18). Located at the corners of the hexagonal-shaped liver lobule, the 
portal triads comprise the portal vein, hepatic artery, and the bile duct (19). Both the portal vein 
and hepatic artery provide blood to the hepatocytes via the sinusoidal endothelial cells and flows 
toward the central vein, located at the center of the liver lobule. The portal vein carries 
deoxygenated and nutrient-rich blood from the intestine while the hepatic artery carries 
oxygenated and low-in-nutrients blood from the aorta. The bile canaliculus carries bile produced 
by the hepatocytes towards the bile duct, which lined by cholangiocytes, to be stored in the gall 
bladder. The central vein passes the blood from the portal vein and hepatic artery to the hepatic 
vein and then to inferior vena cava (20). Finally, hepatocytes fill the liver lobule radially between 
the portal triads and the central vein arranged as plates. 
The hepatocytes are heterogeneous and perform different biochemical and physiological 
functions dependent on their location or zonation of the liver lobule (21, 22). There are three zones 
in the liver: zone 1 is located around the portal triad, zone 3 is located around the central vein, and 
zone 2 is located between the two zones (23). The zone 1 hepatocytes have high availability of 
oxygen and have elevated levels of glucose delivery, gluconeogenesis, urea synthesis, fatty acid 
oxidation, cholesterol synthesis, sulfation, and glutathione and glutathione peroxidase. In contrast, 
the zone 3 hepatocytes have low availability of oxygen and have elevated levels of glucose uptake, 
glycolysis, glutamine synthesis, lipogenesis and ketogenesis, bile acid synthesis, glucuronidation, 
glutathione transferase, and cytochrome P450 enzyme. Finally, zone 2 hepatocytes have 




1.1.3 Maternal liver during pregnancy 
Very little information is available on the maternal liver growth and adaptations to 
pregnancy in humans and, therefore, most of the information is on rodent studies. The maternal 
liver in rodents increases in size proportionally to the maternal body weight gained during 
midgestation and continues until the end of gestation, which averages to about 20 days, to 
accommodate the rapid growth of the fetus (25, 26). During the enlargement of the maternal liver, 
the total hepatic DNA contents increase by the end of pregnancy without changing the hepatocyte 
ploidy (27, 28). Additionally, the maternal hepatocytes reduce in density due to hepatic 
hypertrophy and express pregnancy-induced hepatic genes such as genes involved in proliferation, 
metabolism, and regeneration (27, 28). Furthermore, maternal liver biochemical profile changes 
markedly during pregnancy (29). In the maternal serum, alkaline phosphatase (ALP) and alpha-
fetoprotein (AFP) increases, total protein and albumin decreases, and alanine aminotransferase 
(ALT), gamma-glutamyl transpeptidase (GGT), and bilirubin do not change during pregnancy (29-
31). Moreover, the maternal hepatic enzymes responsible for drug and lipid metabolisms such as 
cytochrome P450 (CYP) change during pregnancy such as the expression of CYP1A2 decreases 
whereas CYP2D6 and CYP3A4 increases (32). The maternal liver then returns to its pre-pregnancy 
size after parturition in ten days without lactation, whereas the maternal liver remains enlarged 
with lactation (28). Interestingly, we found that, when compared with nonpregnant mice, the 
highest activated maternal hepatic gene by the end of gestation is Ascl1. Our goal is to investigate 
whether this molecule plays a role in maternal hepatic adaptations to pregnancy. 
1.1.4 Maternal liver diseases during pregnancy 
Maternal liver diseases during pregnancy are uncommon and affect about 3% of pregnancies; 




There are pregnancy-dependent and -independent maternal liver diseases that affect both the 
mother and the fetus. Pregnancy-dependent maternal liver diseases include hyperemesis 
gravidarum (HG); intrahepatic cholestasis of pregnancy (ICP); preeclampsia, eclampsia, and 
HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome; and acute fatty 
liver of pregnancy (AFLP). Pregnancy-independent maternal liver diseases include preexisting 
liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, autoimmune 
hepatitis (AIH), primary biliary cholangitis (PBC), Wilson disease (WD), cirrhosis, and portal 
hypertension. Currently, there is a lack of research in maternal liver diseases during pregnancy, 
which, therefore, challenges both hepatologists and gynecologists in diagnosing and treating the 
affected patients that also guarantees the safety of the growing fetus. 
1.2 Pregnancy 
1.2.1 Maternal metabolic changes 
To provide an energy source for the development of the placenta and fetus, maternal 
metabolism changes such as lipid anabolism and catabolism (35, 36). The anabolic phase of lipids 
begins during the first and second trimesters where the maternal tissues synthesize and deposit 
lipids to be stored as exogenous metabolic energy for the growing fetus (37, 38). By the third 
trimester, the catabolic phase of lipids activates and begins to breakdown the stored lipids to 
provide as an energy fuel for the developing fetus (39). Additional energy sources include glucose, 
which is the major energy source to the growing fetus; fatty acids, which are essential for fetal 
tissue development and organogenesis; cholesterol, which is essential for cell membrane fluidity 
as well as cell proliferation and differentiation; and ketone bodies, which are essential as a glucose 




metabolic adaptations to pregnancy are necessary and essential to provide energy for the 
developing fetus and successful pregnancy. However, how these metabolic changes are regulated 
remains largely unknown. 
1.2.2 Maternal physiologic changes 
Maternal nonhepatic organs including the heart, lung, blood, gastrointestinal tract, pancreas, 
spleen, and kidney exhibit a variety of physiological changes during gestation. 
1.2.2.1 Heart, lung, and blood 
The function of the heart is to pump blood and provide the metabolic needs to organs and 
tissues of the body. To circulate the blood around the body, the cardiac muscle cells, also known 
as cardiomyocytes, contract rhythmically at a rate of 60 to 100 beats per minute caused by the 
electrical impulses from the sinoatrial (SA) node (45). The heart has two chambers, each having 
an atrium and a ventricle (46). In brief, deoxygenated blood from the vena cava flows into the right 
atrium and enters the right ventricle (47, 48). The blood then exits the heart and enters the 
pulmonary circulation via the pulmonary artery where it exchanges carbon dioxide with oxygen 
from the capillaries in the lungs by diffusion. The oxygenated blood then flows into the pulmonary 
artery and enters back into the heart in the left atrium and into the left ventricle. The mitral valve 
shuts preventing the backflow of the blood in the direction of the atrium. Then the blood exits the 
heart and enters the systemic circulation by flowing into the aorta where organs and tissues take 
up oxygen and exchanges with carbon dioxide. Finally, the deoxygenated blood flows back into 
the vena cava. 
To deliver nutrients to the increasing metabolic needs of the growing fetus, the maternal 




in red and white blood cells, while cardiac output increases due to an increase in stroke volume, 
which in turn increases the heart rate (49-55). As a consequence, the maternal lung increases 
oxygen intake by increasing the amount of air inhaled and exhaled while hyperventilating due to 
the growing fetus pushing up against the maternal diaphragm and causing a decrease in the total 
lung capacity (51, 56-59). Additionally, the systemic vascular resistance, systolic blood pressure, 
and diastolic blood pressure decrease during pregnancy (60, 61). Due to the increased 
hemodynamic stress during pregnancy, the maternal heart results in hypertrophy indicated by 
increased chamber size and wall thickness, which involves various extracellular matrix (ECM) 
proteins, signaling pathways, microRNAs, ubiquitin-proteasome system, and hormones (62-64). 
Nevertheless, pregnancy-induced physiological hypertrophy of the maternal heart requires further 
mechanistic studies. 
 
1.2.2.2 Gastrointestinal tract and gut microbiome 
The function of the gastrointestinal tract, which includes the mouth, pharynx, esophagus, 
stomach, and small and large intestines, is to digest and absorb food and eliminate wastes (65). 
During pregnancy, the gastrointestinal tract changes and causes nausea and vomiting during the 
first trimester; the mechanism for the physiological changes may be due to the hormonal change 
of progesterone that decreases its motility (66, 67). Additionally, human chorionic gonadotropin 
(hCG) may play a role in causing nausea and vomiting as the levels of hCG positively correlates 
to the severity of the symptoms (68). 
The gut microbiome plays an important role in human health that includes metabolism of 
food and drugs, protection against pathogens and epithelial injury, promotion of fat storage and 
angiogenesis, and modification of the nervous system and the immune system by cross-talking to 




the gut microbiome contains the most diverse population of bacteria in the human body (71). 
Multiple factors, such as the delivery mode, postnatal factors, and diet, shape the infant’s 
microbiome (72). The first microbiome colonization in the human body occurs at birth, which 
depends on vaginal or cesarean delivery. The vaginally-delivered infants have a microbiome that 
resembles the maternal vaginal microbiome; however, cesarean-delivered infants have a 
microbiome that resembles the maternal skin and environmental microbiome (73). For a newborn 
infant, exposures to antibiotics, breastfeeding or formula, solid foods, host genetics, and 
environment further changes the infant’s microbiome (72). As the toddler grows and consumes an 
adult diet, the microbiome slowly shifts toward an adult-like microbiome. Dysbiosis of 
microbiome caused by a bloom of pathogens and a loss of commensal bacteria and diversity results 
in diseases such as type 1 and 2 diabetes, obesity, colorectal cancer, rheumatoid arthritis (RA), and 
inflammatory bowel diseases (IBD) (70, 74). Therefore, maintaining a healthy microbiome is 
crucial to having a healthy life. 
The microbiome changes, most prominently in the vagina and gut, to adapt to the 
physiological and immunological changes of the host during pregnancy (75-77). By the end of the 
pregnancy, the microbiome diversity and number decrease. The Lactobacillus species, which 
produces lactic acid that prevents the growth of pathogens, becomes the most abundant bacterial 
species followed by Clostridiales, which is associated with mental health improvement, 
Bacteroidales, which produces the most abundant capsular polysaccharides for its survival in the 
gut, and Actinomycetales, which produces antibiotics (77-81). The healthy microbiome during 
pregnancy is associated with preventing preterm birth due to bacterial vaginosis, gestational 
diabetes due to decreased diversity of the microbiome, and obesity due to reduced levels of 




developing conditions such as obesity, diabetes, allergies, altered brain development, and high 
blood pressure (84-87). Therefore, a healthy microbiome during pregnancy is essential not only 
for the health of the mother but also for the fetus during development and postnatal growth. 
1.2.2.3 Pancreas 
The function of the pancreas, which is composed of dorsal and ventral buds, is to produce 
digestive enzymes and hormones to break down food and regulate blood glucose levels, 
respectively (88). The exocrine cells of the pancreas, the acinar cells, account for 98% of the 
pancreatic mass and produce digestive enzymes such as lipase, protease, and amylase, which travel 
along the pancreatic duct to the small intestine and aid in the breakdown of foods (89, 90). The 
endocrine cells, located in the islets of Langerhans of the pancreas, account for 2% of the 
pancreatic mass and produce hormones such as amylin, C-peptide, and insulin by the β-cells, 
glucagon by the α-cells, somatostatin by the δ-cells, pancreatic polypeptide (PP) by the γ-cells, 
and ghrelin by the ε-cells to regulate blood sugar levels. Therefore, the pancreas regulates digestion 
and blood glucose homeostasis. 
During the first trimester, the fetal blood glucose concentration is lower than the maternal 
blood glucose, and, therefore, the fetus receives the maternal glucose by passive diffusion using 
facilitative glucose transporters present in the placenta; however, during late pregnancy, the fetus 
actively redirects the maternal blood glucose that may result in maternal hypoglycemia (91-94). 
Additionally, in mice, the maternal β-cells, mostly from preexisting maternal β-cells, proliferate 
and increase the production of insulin (95, 96). The β-cell expansion in pregnancy may be due to 
the maternal islets producing serotonin and placenta producing placental lactogen (97, 98). To 
prevent low maternal blood glucose, the placenta secrets placental hormones, such as placental 




upregulate hepatic gluconeogenesis (99). By the end of pregnancy, prolactin secreted by the 
maternal pituitary and progesterone secreted by the placenta may block the proliferation of the 
maternal β-cells and initiates cell death by apoptosis (100-102). 
1.2.2.4 Spleen 
The spleen has two compartments called the red pulp, which filters the blood, recycles irons, 
and produces antibodies, and the white pulp, which contains lymphoid cells for the innate and 
adaptive immune response (103). The maternal spleen in mice increases in size until midgestation 
and decreases to the nonpregnant state before parturition (104, 105). Coinciding with the splenic 
growth, the spleen increases in the erythropoietic activity and upregulates erythroid-associated 
genes (104, 106). Furthermore, maternal spleen in humans also increases in size throughout 
pregnancy (107, 108). Therefore, the enlargement of the maternal spleen may represent a normal 
physiological event. 
1.2.2.5 Kidney 
The function of the kidney is to maintain homeostasis of the body by filtering nitrogenous 
waste products, such as creatinine, urea, and ammonia; reabsorbing essential substances, such as 
water, glucose, and electrolytes; maintaining acid-base balance; and secreting calcitriol and 
erythropoietin hormones (109, 110). 
The maternal kidney adapts to pregnancy both anatomically and functionally. During 
pregnancy, the maternal kidney increases in size until parturition due to the increase in the blood 
flow and fluid retention without increasing the number of nephrons and returns back to its normal 
size within half a year (111-114). In the maternal kidney, the glomerular filtration rate (GFR) and 




maternal blood volume and human chorionic gonadotropin (hCG) (115, 116). Additionally, 
changes in the biochemistry of the urine and blood are due to the increase in the clearance of 
creatinine, uric acid, and urea, which result in the decrease of maternal serum creatinine and blood 
urea nitrogen (BUN) (50, 117). Consequently, the changes in the filtrations cause an increase in 
the water volume of the maternal body and provide water to the developing placenta and fetus 
(117).  
1.3 Mammalian achaete-scute homology (Mash) family 
Currently, there are five mammalian achaete-scute homolog (Mash) family members: Ascl1, 
Ascl2, Ascl3, Ascl4, and Ascl5. Information regarding the first three members, Ascl1, Ascl2, and 
Ascl3, are available in the literature; however, studies on the remaining two members, Ascl4 and 
Ascl5, are lacking. Here, we summarize the current knowledge of Ascl1, Ascl2, and Ascl3. 
1.3.1 Ascl1 
The first member of the mammalian achaete-scute homolog (Mash) is achaete-scute 
homolog 1 (Ascl1). Located on chromosome 12q22-q23 in humans and chromosome 10 in mice, 
Ascl1 is a basic helix-loop-helix transcription factor that regulates neuronal cell fates in both the 
central nervous system (CNS) and the peripheral nervous system (PNS) (118-120). During human 
development, genetic disorders associated with the nervous system due to Ascl1 mutation include 
congenital central hypoventilation syndrome (CCHS) and Haddad syndrome, whereas, in rodent, 
ablation of Ascl1 results in developmental defects of neuronal lineages and postnatal death (120-
122). In the adult, thymus, brain, spinal cord, and B lymphoblasts express Ascl1 (123). 




subtypes (124). Therefore, Ascl1 regulates development, physiological and pathological conditions, 
and cell fate. 
Rodent studies show that the function of Ascl1 during development is proliferation, cell cycle 
exit, and/or differentiation in neural stem cells (125). The neural stem cells express Ascl1 in an 
oscillatory manner due to its repressor Hes1 autonomously oscillating via a negative feedback loop 
every 2 hours (126, 127). Neural stem cells without the expression of Ascl1 proliferate slowly; 
however, neural stem cells expressing Ascl1 in an oscillatory fashion activates proliferation 
whereas a sustained expression of Ascl1 results in cell cycle exit and differentiation (125). 
Therefore, Ascl1 governs in maintaining neural stem cells.  
Before neurogenesis, neural stem cells maintain their undifferentiated state by activating the 
Notch signaling as a result of a neighboring neuron or another neural stem cell expressing constant 
or oscillating Ascl1 and Delta-like 1 (Dll1) levels, respectively (128). Neurons constantly express 
Ascl1, which activates the expression of Dll1 that binds to the transmembrane receptor Notch of 
their neighboring neural stem cells. The neural stem cells activate the Notch signaling pathway by 
releasing the Notch intracellular domain (NCID) from the Notch receptor, which translocates to 
the nucleus, binds with mastermind-like (Maml) and recombining binding protein suppressor of 
hairless (Rbpj), activates Hes1 expression that inhibits Ascl1 expression, and maintain their stem 
cell properties by a process known as lateral inhibition. Another method in maintaining an 
undifferentiated neuronal state is ‘salt-and-pepper pattern’ (129). In this method, the neighboring 
neural stem cells will take turns expressing Ascl1 and Dll1 to activate the Notch signaling in their 
neighboring neural stem cells. As a result, Ascl1 controls the Notch signaling and the maintenance 




After neurogenesis, the neural stem cells lose the Dll1 expression and differentiate into 
mature neural cells (128). Various cells express Ascl1 such as the chromaffin cells, glomus cells, 
oligodendrocytes, olfactory sensory neurons, pulmonary neuroendocrine cells, and parafollicular 
cells (130-137). During pathological conditions, medullary thyroid cancers and small cell lung 
cancers highly express Ascl1 by promoting metastasis and preventing apoptosis (138, 139). 
Reprogramming studies in vitro show that Ascl1 reprograms postnatal astrocytes into GABAergic 
neurons; Ascl1 and Sox2 reprogram human pericytes also into GABAergic neurons; and Ascl1, 
Brn2, and Mytl1 reprogram hepatocytes into neuronal cells (140-144). Therefore, Ascl1 influences 
in maintaining the neural stem cells and controlling neuronal fate, while the upregulation of Ascl1 
expression characterizes subpopulations of cancer cells and overexpression results in 
reprogramming non-neural cells into neural subtypes. 
1.3.2 Ascl2 
The second member of Mash is Ascl2. Located on chromosome 11p15.5 in humans and 
chromosome 7 in mice, Ascl2 is a basic helix-loop-helix transcription factor expressed only in the 
paternal allele due to genomic imprinting (145). Variety of different organs and cells express Ascl2 
including the placenta, intestine, skeletal muscle, follicular helper T cells, and colon, lung, and 
gastric carcinoma (146-150). 
The ovum transcribes Ascl2 during oogenesis and, after fertilization, the trophoblast lineage 
cells express Ascl2 that continues to the development of the placenta (146). The placenta is a highly 
specialized temporary organ during pregnancy that helps in the growth of the fetus by exchanging 
metabolic products and wastes, protecting the fetus against xenobiotics and infections, and 
releasing hormones between maternal and fetal circulations (151). In the placenta, the 




Ascl2 in mice yielded in a significantly smaller placenta due to the lack of the spongiotrophoblast 
layer formation, which results in the death of the embryos around embryonic day (E) 10 (152). 
Therefore, Ascl2 influences the development of the placenta and the continuation of the pregnancy.  
The Ascl2 expression is also present in the adult intestinal epithelium, especially in the Lgr5+ 
stem cells in the crypt base of the intestine (147). The intestine is part of the digestive tract and 
regulates the absorption of nutrients and water from the food and production of vitamins by the 
microbiome (153). The turnover rate of the intestinal epithelial cell is about 5 days, and, therefore, 
intestinal stem cells direct in maintaining homeostasis and structural integrity of the intestinal 
epithelium (154, 155). Studies show that conditional deletion of Ascl2 in the mouse intestine 
results in the loss of the intestinal stem cells due to an increase in cell apoptosis whereas 
overexpression of Ascl2 does not induce tumorigenesis (147, 156). Therefore, Ascl2 is essential in 
the maintenance and homeostasis of the intestine by sustaining the intestinal stem cells niche. 
A recent study links Ascl2 and muscle stem cells (150). The stem cells of the muscle called 
satellite cells govern postnatal muscle growth and regeneration of damaged muscle by symmetric 
and asymmetric divisions (157, 158). In muscle, myogenic regulatory factors activate myogenesis 
in the satellite cells; however, Ascl2 inhibits the myogenic regulatory factors, which results in 
inhibition of proliferation, differentiation, and fusion of myoblasts (150). Additionally, 
overexpression of Ascl2 impairs muscle repair from injury. Therefore, Ascl2 hinders the self-
renewal and maintenance of the postnatal satellite cells. 
The initiation and development of the follicular helper T cells during an immune response 
requires Ascl2 in both humans and mice (159). The follicular helper T cells are essential for the 
development of the germinal centers where the maturation of B cells and the production of 




by activating Ascl2-dependent genes while the ablation of Ascl2 results in the inhibition of the 
follicular helper T cells differentiation (159). As a result, Ascl2 directs in initiating the follicular 
helper T cell development and function during an immune response to infection. 
Recently, multiple studies identify Ascl2 expression in subpopulations of lung, colon, and 
stomach cancers. Lung, colon, and stomach cancers are the first, third, and fourth in males and 
second, third, and fifth in females, respectively, type of cancer-related mortality worldwide (161). 
A subpopulation of lung squamous cell carcinoma, which is part of a non-small-cell lung 
carcinoma activates the non-canonical Wnt signaling pathway and express increased levels of 
Ascl2 when compared with normal bronchi and lung adenocarcinoma (149, 162). In colon cancer 
cells, high expression of Ascl2 associates with tumor malignancy such as proliferation, colony 
formation, invasion, migration, growth, and epithelial-mesenchymal transition (EMT) (163, 164). 
Finally, in stomach cancer, overexpression of Ascl2 promotes cancer development by inducing 
EMT (165). Therefore, Ascl2 influences during normal development and tumor metastasis. 
1.3.3 Ascl3 
The third member of Mash is Ascl3. Located on chromosome 11p15.3 in humans and 
chromosome 7 in mice, Ascl3 is a basic helix-loop-helix transcription factor expressed in the 
salivary glands (166, 167). Salivary glands secrete continuous saliva that is essential in the function 
and health of the oral mucosa such as lubrication of the oral cavity, preventing the growth of 
microbes, remineralization of the enamel, facilitating soft tissue repair, and digestion (168). During 
development, subpopulations of the salivary glands progenitor cells of the acinar and ductal cells 
express Ascl3 (169, 170). Ablation of Ascl3 results in smaller development of the salivary glands 
due to a reduced cell proliferation without affecting the function (171). Therefore, Ascl3 is 




A recent study shows that, in addition to the progenitor cells of the salivary glands, the 
developing olfactory epithelium in the nasal cavity, which is the peripheral organ for sensing smell, 
also expresses Ascl3 as early as embryonic day (E) 12.5 (172). During development, Ascl3 is 
present in the multipotent horizontal basal cells of the olfactory epithelium, which are the 
progenitor cells of the microvillar cells and the Bowman’s glands. Nevertheless, the ablation of 
Ascl3 does not influence the differentiation of the multipotent horizontal basal cells. Furthermore, 
during injury-induced regeneration of the olfactory epithelium, the horizontal basal cells express 
Ascl3 and regenerate the microvillar cells and the Bowman’s glands. Therefore, Ascl3 expression 
activates in injury and repair of the olfactory epithelium while its involvement in differentiation 
and homeostasis of the olfactory epithelium requires further research. 
1.4 Hypothesis 
While the maternal liver adapts to pregnancy, the hepatic cells activate a proneural gene 
Ascl1 during mid to late gestation when the placenta and fetus grow most rapidly. We hypothesize 







Ascl1-/- (Ascl1fl/fl;R26rtTA/rtTA;tetOCre/-) mice delete Ascl1 in the whole body, except the brain 
and testes, with the administration of doxycycline. For the generation of Ascl1-/- mice, 
Ascl1fl/fl;R26EYFP/EYFP mice, a generous gift from Dr. Guillemot (The Francis Crick Institute, 
Midland Road, London NW 1AT, UK), were crossed with R26rtTA/rtTA (B6.Cg-
Gt(ROSA)26Sortm1(rtTA*M2)Jae/J; Stock No: 006965) mice and tetOCre/- (B6.Cg-Tg(tetO-cre)1Jaw/J; 
Stock No: 006234) mice from the Jackson Laboratory (Bar Harbor, Maine, USA). Selective 
breeding was required to remove the EYFP allele and replace it with the rtTA allele. Ascl1+/+ 
(Ascl1+/+;R26rtTA/rtTA;tetOCre/-) mice were used as controls. 
Cell-Ascl1Cre/- (Ascl1Cre/fl;R26EYFP/EYFP) mice delete Ascl1 in Ascl1-expressing cells with the 
administration of tamoxifen. For the generation of cell-Ascl1Cre/- mice, Ascl1fl/fl;R26EYFP/EYFP mice 
were crossed with Ascl1Cre/+ (Ascl1tm1.1(Cre/ERT2)Jejo/J; Stock No: 012882) mice from Jackson 
Laboratory. Cell-Ascl1Cre/+ (Ascl1Cre/+;R26EYFP/EYFP) mice were used as controls. 
For the generation of hep-Ascl1-/- mice, which delete Ascl1 in the maternal liver, 
Ascl1fl/fl;R26EYFP/EYFP mice were used as both experimental and control by injecting with a virus 
containing Cre or null vectors, respectively. 
All animal studies were performed in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and with the approval from the Indiana 
University-Purdue University Indianapolis Animal Care and Use Committee. All mice were 
maintained on a 12-hour light/12-hour dark cycle (7 AM on and 7 PM off) at 22 ± 1°C. Mice were 




2.2 Genomic PCR 
Genomic DNA was prepared from mouse ear snips using the modified HotSHOT method 
(173). In brief, mouse ears were lysed by incubating in a 25 mM NaOH/0.2 mM EDTA solution 
at 98°C for 1 hour and neutralized with 40 mM Tris-HCl (pH 5.5). All mice were genotyped by 
polymerase chain reaction (PCR) using KAPA Taq PCR Kits (Kapa Biosystems, Inc., Wilmington, 
MA, USA). Specific primers purchased from Integrated DNA Technologies (Coralville, IA, USA) 
were used to detect the wild type and mutant alleles. Genotyping PCR was performed as per 
directions with modification from the vendor using Mastercycler Pro (Eppendorf, 950030010). 
The PCR products, after adding ethidium bromide solution (IBI Scientific, IB40075), were 
separated by agarose gel electrophoresis and visualized using a UV transilluminator. 
For Ascl1-/- (Ascl1fl/fl;R26rtTA/rtTA;tetOCre/-) mouse line, genotyping was performed with a 
modification in the PCR conditions (174). Primers Ascl1 Forward and Ascl1 Wild type Reverse 
were used to detect the Ascl1 wild type allele (342 bp), and primers Ascl1 Forward and Ascl1 
Mutant Reverse were used to detect floxed Ascl1 allele (857 bp) (Fig. 1A) (Table 1). PCR 
conditions were 35 cycles of 94°C/30 sec; 69°C/30 sec; 72°C/90 sec. Primers oIMR8545 and 
oIMR8546 were used to detect the rtTA-negative allele (650 bp), and primers oIMR8545 and 
oIMR8052 were used to detect the rtTA-positive allele (340 bp) (Fig. 1B) (Table 1). PCR 
conditions were 35 cycles of 94°C/30 sec; 65°C/1 min; 72°C/1 min. Primers oIMR7338 and 
oIMR7339 were used as an internal positive control (324 bp), and primers oIMR1084 and 
oIMR1085 were used to detect Cre transgene (~100 bp) (Fig. 1C) (Table 1). PCR conditions were 
35 cycles of 94°C/30 sec; 70°C/1 min; 72°C/1 min. Primers EYFP Forward and EYFP Wild type 
Reverse were used to detect EYFP-negative allele (600 bp), and primers EYFP Forward and EYFP 
Mutant Reverse were used to detect EYFP-positive allele (320 bp) (Fig. 1D) (Table 1). PCR 




For cell-Ascl1Cre/- (Ascl1Cre/fl;R26EYFP/EYFP) mouse line, primers 10841 and 10842 were used 
to detect the Cre-negative allele (418 bp), and primers 10843 and 10653 were used to detect the 
Cre-positive allele (~300 bp) (Fig. 1E) (Table 1). PCR conditions were 35 cycles of 94°C/30 sec; 
62°C/30 sec; 72°C/30 sec. Identical primers and PCR conditions were used to detect Ascl1 wild 
type and floxed alleles, and EYFP-negative and -positive alleles as mentioned previously. 
For hep-Ascl1-/- (Ascl1fl/fl;R26EYFP/EYFP) mouse line, identical primers and PCR conditions 
were used to detect Ascl1 wild type and floxed alleles, and EYFP-negative and -positive alleles as 
mentioned previously. 
2.3 Pregnancy model 
Timed pregnancy was performed by mating female mice with wild type male mice to ensure 
that fetuses are heterozygous and have at least one wild type allele. The presence of a copulation 
plug in the morning was designated as gestation day (GD) 1, and plug-positive female mice were 
separated from male mice and housed in individual cages. 
For Ascl1-/- (Ascl1fl/fl;R26rtTA/rtTA;tetOCre/-) mice, doxycycline (Alfa Aesar, J60579) was 
dissolved in Milli-Q water (Millipore Sigma, Z00Q0V0WW) at a concentration of 1 mg/ml in the 
drinking water bottle on GD6 until the mice were sacrificed. For cell-Ascl1Cre/- 
(Ascl1Cre/fl;R26EYFP/EYFP) mice, tamoxifen (Sigma-Aldrich, T5648) was dissolved in 10% ethanol 
and sesame oil (Sigma-Aldrich, S3547), incubated overnight in a shaker at 37°C, injected 
intraperitoneally at a dose of 60 mg/kg on GD13-14, and sacrificed on GD15 and GD18. For hep-
Ascl1-/- (Ascl1fl/fl;R26EYFP/EYFP) mice, adeno-associated viruses expressing Cre (Addgene, AV-8-







Figure 1. Genotyping Gel Image. DNA was extracted from ear snips and polymerase chain 
reaction (PCR) was performed with specific primers (Table 1) to determine the presence of (A) 
floxed Ascl1 allele, (B) rtTA allele, (C) Cre transgene downstream of tetO promoter, (D) EYFP 
allele, and (E) Cre allele downstream of Ascl1 promoter. Ascl1, achaete-scute homolog 1; Cre, 
Cre recombinase; EYFP, enhanced yellow fluorescent protein; R26, Rosa26 promoter element; 












vein at a dose of 1x1012 genomic copies per mouse on GD8, and mice were sacrificed on GD15, 
GD18, and GD19. Adeno-associated viruses with a null vector (Addgene, AV-8-PV0148) were 
used as controls. 
2.4 Tissue collection and histology 
Nonpregnant and maternal mouse serum and tissues, such as spleen, kidney, heart, lung, and 
placenta, were collected and weighed on various gestation days. Tissues were embedded in optimal 
cutting temperature (OCT) compound (Fisher Scientific, 23-730-571) on heptane cooled in dry ice 




at -80°C for protein and RNA extraction. The remaining tissues were fixed in 10% neutral buffered 
formalin (NBF) for 72 hrs and sent to the Histology Core at the Indiana Center for Musculoskeletal 
Health (Indiana University School of Medicine) to be embedded in paraffin and sectioned at 5 µm 
for hematoxylin and eosin (H&E) staining and histological analysis. Maternal pancreatic tissues 
were fixed in 4% paraformaldehyde (PFA) (Sigma Aldrich, 818715) for 24 hrs, embedded in 
paraffin, and sectioned at 7 µm for 5 layers at 50 µm apart. 
2.5 Immunohistochemistry 
Formalin-fixed and paraffin-embedded maternal liver and placental tissue sections were 
deparaffinized in xylene, hydrated in alcohol gradients, epitope retrieved in citrate buffer (10 mM, 
pH 6.0) with 0.1% Tween-20 (Fisher Scientific, BP337-100) for 30 min, cooled to room 
temperature for 3 hrs, and endogenous peroxidase activity blocked using 3% H2O2 for 10 min. The 
sections were blocked with the appropriate 2% normal serum (Jackson Immunoresearch) in 
Dulbecco's phosphate-buffered saline (DPBS) (Quality Biological, 114-059-101) for 1 hr at room 
temperature. The sections were incubated with the appropriate diluted primary antibody (Table 2) 
in DPBS at 4°C overnight. The next day, the sections were incubated with the appropriate 
biotinylated secondary antibody (Jackson Immunoresearch) for 1 hr followed by Vectastain Elite 
ABC HRP Kit (Vector Laboratories, PK-6100) for 30 min. The signals were developed by 
incubating the slides with a 3,3’-diaminobenzidine (DAB) solution (Sigma Aldrich, D8001). The 
sections were counterstained in hematoxylin (Leica, 3801575) for 1 min. Finally, the sections were 




2.6 Hepatocyte density 
Liver sections stained with β-Catenin were used to count hepatocytes in five random fields 
of view at 400x magnification, acquired by Leica DM2000 microscope, using ImageJ (175). 
 
Table 2. List of Antibodies for Immunohistochemistry 
 
 
2.7 Oil Red O staining 
This staining method is used to detect fats such as lipids. Liver tissues were embedded in 
OCT compound (Fisher Scientific, 23-730-571) on dry-ice cooled heptane, stored at -80°C, and 
sectioned at 10 µm using Leica CM3050 S Research Cryostat (Leica, 14047033518). In brief, the 
sections were air-dried at 37°C for 15 min, fixed in 10% NBF at room temperature for 10 min, and 
rinsed in water. Next, the sections were stained in the Oil Red O staining solution (Sigma-Aldrich, 
O0625) for 15 min, rinsed in 60% isopropanol (Acros Organics, 67-63-0) for 3 min and in water, 
and mounted (Vector Laboratories, H-5501). The slide images were acquired by the Leica 
DM2000 microscope and the stained area quantified using ImageJ (175). 
2.8 Periodic Acid Schiff staining 
This staining method is used to detect polysaccharides such as glycogen. Formalin-fixed and 




hydrated in alcohol gradients, oxidized in 0.5% periodic acid solution (Santa Cruz, sc-215695, 
1:100) for 5 min, and rinsed in water. Next, the sections were incubated in Schiff’s reagent solution 
(Santa Cruz, sc-301793) for 15 min, rinsed in water, and counterstained in hematoxylin (Leica, 
3801575) for 1 min. Finally, the sections were dehydrated in alcohol gradients, incubated in xylene, 
and mounted (Vector Laboratories, H-5501). The slide images were acquired by the Leica 
DM2000 microscope. 
2.9 β-Cell mass 
Pancreatic sections stained with insulin (Santa Cruz, sc-9168, 1:100) were used to quantify 
insulin-positive β cell mass by the Eli Lilly and Company (Indianapolis, IN). 
2.10 In situ hybridization 
In situ hybridization was performed using the appropriate probes and RNAscope 2.5 HD 
Assay (Advanced Cell Diagnostics, 322300) as per directions by the manufacturer. The following 
probes were used: Ascl1 (Advanced Cell Diagnostics, 476321), CD133 (Advanced Cell 
Diagnostics, 412221), Igf2 (Advanced Cell Diagnostics, 437671), PL-I (Advanced Cell 
Diagnostics, 405521), and PL-II (Advanced Cell Diagnostics, 423681). A positive control probe 
Ppib (Advanced Cell Diagnostics, 310043) and a negative control probe DapB (Advanced Cell 
Diagnostics, 313911) were used to determine the efficacy of the protocol. In situ hybridization 
staining images were acquired by Leica DM2000 microscope. 
2.11 Western blotting 
Tissue homogenates (10-30 µg) were prepared from the snap-frozen liver and placental 




Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78443) as per directions 
by the manufacturer. Protein concentrations were determined by Pierce BSA Protein Assay 
Standards (Thermo Fisher Scientific, 23208) using NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific, ND-2000). Proteins were separated under reducing conditions on NuPAGE 4-
12% Bis-Tris Midi Protein Gels (Invitrogen, NP0336BOX or WG1403BOX) and transferred to 
PVDF transfer membranes (Thermo Fisher Scientific, 88518). The membranes were then blocked 
in 5% nonfat milk or BSA (Fisher Scientific, BP1605-100) in Tris-buffered saline (TBS) with 0.1% 
Tween-20 (Fisher Scientific, BP337-100). The membranes were incubated with the appropriate 
diluted primary antibody in 5% nonfat milk or BSA (Table 3). Immunoreactive proteins were 
detected by SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, 
34577) according to the manufacturer’s protocol and imaged using ImageQuant LAS 4000 Mini 
(General Electric Life Sciences, 28-9558-15). The relative expression of the protein signals was 
quantified using ImageJ (175). 
2.12 Intraperitoneal glucose tolerance tests and insulin measurements 
For the glucose tolerance test, data were collected from two different time points on gestation 
day (GD) 18 and GD19. On GD18, pregnant hep-Ascl1-/- mice were fasted for 6 hrs (9 AM to 3 
PM) in a clean cage with woodchip bedding and water and injected intraperitoneally (i.p.) with D-
glucose (Sigma, G5767) dissolved in Milli-Q water at 2 g of glucose per kg of body weight. Blood 
glucose levels were measured via tail vein using a glucometer (OneTouch Ultra 2) before glucose 
injection (T=0) and at 15, 30, 60, 90, and 120 min after glucose injection. On GD19, the hep- 
Ascl1-/- mice were fasted for 6 hrs, injected with glucose, and blood samples were collected before 




Translation Core at the IU School of Medicine Center for Diabetes and Metabolic Diseases 
(Indiana University School of Medicine). Ascl1fl/fl mice were used as controls. 
 
Table 3. List of Antibodies for Western Blotting 
 
 
2.13 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA was isolated from snap-frozen liver tissue using TRIzol reagent (Invitrogen, 
15596018) as per directions by the manufacturer. Complementary DNA (cDNA) was synthesized 
from 1 µg of total RNA, which was quantified by NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific, ND-2000), using Verso cDNA kit (Thermo Fisher Scientific, AB1453B) and 




TaqMan Gene Expression Master Mix (Applied Biosystems, 4369016) or PowerUp SYBR Green 
Master Mix (Applied Biosystems, A25742) with specific TaqMan gene probes (Tables 4 and 5) 
(176). The qRT-PCR was performed using the 7300 Real-Time PCR System (Applied Biosystems, 
4351103) and analyzed by the 7300 System SDS RQ Study Software (Applied Biosystems, 
4350814). The qRT-PCR conditions using TaqMan Gene Expression Master Mix were UNG 
incubation (50°C/2 min), polymerase activation (95°C/10 min), and 40 cycles of PCR (95°C/15 
sec, 60°C/1 min). The qRT-PCR conditions using PowerUp SYBR Green Master Mix were UDG 
activation (50°C/2 min), polymerase activation (95°C/2 min), 40 cycles of PCR (95°C/15 sec, 
60°C/15 sec, 72°C/1 min), and dissociation curve (95°C/15 sec, 60°C/30 sec, 95°C/15 sec). 
Relative gene expression was calculated by the comparative CT method (ΔΔCt) and normalized 
to 18S rRNA. 
 
Table 4. List of TaqMan qRT-PCR Primers 
 
 
2.14 RNA sequencing 
Total RNA was isolated from snap-frozen liver tissue using the RNeasy Plus Mini Kit 
(Qiagen, 74134) as per directions by the manufacturer. RNA sequencing (RNA-seq) was 




Medicine). The concentration and quality of total RNA samples were first assessed using Agilent 
2100 Bioanalyzer.  
 




As stated by the Center for Medical Genomics Core, a RIN (RNA Integrity Number) of five 
or higher was required to pass the quality control. Then five hundred nanograms of RNA per 
sample were used to prepare a single-indexed strand-specific cDNA library using TruSeq Stranded 
mRNA Library Prep Kit (Illumina). The resulting libraries were assessed for its quantity and size 
distribution using Qubit and Agilent 2100 Bioanalyzer. Two hundred picomolar pooled libraries 
were utilized per flowcell for clustering amplification on cBot using HiSeq 3000/4000 PE Cluster 




3000/4000 PE SBS Kit. A Phred quality score (Q score) was used to measure the quality of 
sequencing. More than 90% of the sequencing reads reached Q30 (99.9% base call accuracy). 
The sequencing data were first assessed using FastQC (Babraham Bioinformatics, 
Cambridge, UK) for quality control. Then all sequenced libraries were mapped to the mouse 
genome (UCSC mm10) using STAR RNA-seq aligner with the following parameter: “--
outSAMmapqUnique 60”. The reads distribution across the genome was assessed using bamutils 
(from ngsutils). Uniquely mapped sequencing reads were assigned to mm10 refGene genes using 
featureCounts (from subread) with the following parameters: “-s 2 –p –Q 10”. Quality control of 
sequencing and mapping results were summarized using MultiQC. Genes with read count per 
million (CPM) < 0.5 in more than 5 of the samples were removed. The data were normalized using 
TMM (trimmed mean of M values) method. Differential expression analysis was performed using 
edgeR and Ingenuity Pathway Analysis (IPA) with +/- 2-fold change and P < 0.05. False discovery 
rate (FDR) was computed from p-values using the Benjamini-Hochberg procedure. 
2.15 Serum biochemistry 
Nonpregnant and pregnant maternal blood were collected on gestation day (GD) 15 and 
GD18 and left to clot at room temperature for at least 1 hr. After two centrifugations at 3000 RPM 
and collecting the supernatant, the serum was analyzed by the Eli Lilly and Company (Indianapolis, 
IN). 
2.16 Microbiome 16S sequencing 
Total microbial DNA was isolated from the snap-frozen cecal sample using the PureLink 




Microbiome 16S sequencing was performed and analyzed by the Zymo Research Corporation 
(Irvine, CA).  
As stated by the Zymo Research Corporation, bacterial 16S ribosomal RNA gene targeted 
sequencing was performed using the Quick-16S NGS Library Preparation Kit (Zymo Research, 
Irvine, CA). The bacterial 16S primers used amplified the V3-V4 region of the 16S rRNA gene. 
These primers have been custom-designed by Zymo Research to provide the best coverage of the 
16S gene while maintaining high sensitivity. They amplify the V3-V4 region of the 16S rRNA 
gene. The sequencing library was prepared using an innovative library preparation process in 
which PCR reactions were performed in real-time PCR machines to control cycles and therefore 
prevent PCR chimera formation. The final PCR products are quantified with qPCR fluorescence 
readings and pooled together based on equal molarity. The final pooled library was cleaned up 
with Select-a-Size DNA Clean & Concentrator (Zymo Research, Irvine, CA), then quantified with 
TapeStation and Qubit. The final library was sequenced on Illumina MiSeq with a v3 reagent kit 
(600 cycles). The sequencing was performed with >10% PhiX spike-in. 
Amplicon sequences were inferred from raw reads using the Dada2 pipeline. Chimeric 
sequences were also removed with the Dada2 pipeline. Taxonomy assignment, composition bar 
charts, alpha-diversity, and beta-diversity analyses were performed with Qiime v.1.9.1. Taxa that 
have an abundance significantly different among groups were identified by LEfSe with default 
settings if applicable. Other analyses were performed with in-house scripts. Differential expression 
analysis was assessed using IPA with +/- 2-fold change and P < 0.05. 
2.17 Statistics 
Sample sizes for all data were at least three mice, which were determined by the success rate 




specific Ascl1 deletion, hep-Ascl1-/- (Ascl1fl/fl;R26EYFP/EYFP) mice were divided randomly into 
experimental and control groups. Statistical analyses were performed using a two-sided unpaired 
Student’s t-test. All data were shown as mean value ± standard deviation (SD). Significance was 






















3.1 Maternal liver activates hepatic Ascl1 during pregnancy 
During pregnancy, the maternal liver adapts to the rapid growth and development of the 
placenta and fetus by changing its gene profile (27, 177). We previously reported the pregnancy-
dependent activation of maternal hepatic Ascl1, a gene associated with neural development in the 
rat (177). We also observed the same activation of hepatic Ascl1 in pregnant mice in our 
unpublished DNA microarray data. To verify our data, we performed a timed-pregnancy 
experiment on C57BL6/J mice and detected the activation of maternal hepatic Ascl1 mRNA (Fig. 
2A). Consistent with the idea that hepatic Ascl1 expresses during pregnancy, qRT-PCR of hepatic 
Ascl1 mRNA expression showed a time-dependence pattern where it remained at a basal level 
from nonpregnant until gestation day (GD) 10 but began to elevate significantly from GD11 until 
GD15 and started to decline in GD18. Surprisingly, when compared to the nonpregnant state, the 
hepatic Ascl1 mRNA exhibited an up to 26,000-fold increase on GD15. In situ hybridization 
detected the expression of Ascl1 mRNA localized in the nucleus and cytosol of the Ascl1-
expressing cells in the maternal liver (Fig. 2B). Thus, pregnancy induces the maternal liver to 







Figure 2. Activation of maternal hepatic Ascl1. (A) Ascl1 mRNA expression in the maternal 
liver. The presence of a copulation plug was designated as gestation day 1. Total RNA was isolated 
from livers of nonpregnant (NP) and pregnant (gestation days 8, 10, 11, 13, 15, and 18) C57BL6/J 
mice. Hepatic Ascl1 mRNA levels were measured using quantitative real-time polymerase chain 
reaction (qRT-PCR) and expressed as the mean fold changes relative to NP controls (± s.d.; n = 3 
for each group). **, P < 0.01; ***, P < 0.001, compared with NP controls. β-Actin mRNA levels 
were used as endogenous controls. (B) Ascl1 mRNA distribution in the maternal liver. Liver 
sections of NP and gestation day 15 C57BL6/J mice subjected to Ascl1 in situ hybridization using 
RNAscope 2.5 HD Assay-BROWN kit. The Ascl1 mRNA is stained dark brown. Ascl1, achaete-
scute homolog 1. 
3.2 Global deletion of Ascl1 
3.2.1 Generation of global inducible Ascl1 knockout mouse model 
To assess the role of maternal hepatic Ascl1 in pregnancy, we generated a global inducible 
Ascl1 knockout (Ascl1-/-) (Ascl1fl/fl;R26rtTA/rtTA;tetOCre/-) mice (Fig. 3A). In this Ascl1-/- mice, the 




transactivator (rtTA). The rtTA activates with the presence of doxycycline and initiates the 
tetracycline-responsive promoter element (tetO) to drive the expression of Cre recombinase to 
delete the loxP-flanked Ascl1 gene. As a result, with the administration of doxycycline, all the cells 
in the body, with the exception of the brain and the testis due to the inability of doxycycline to 
pass the blood-brain barrier and blood-testis barrier, delete Ascl1 (178). For control mice, we 
generated the Ascl1+/+ (Ascl1+/+;R26rtTA/rtTA;tetOCre/-) mice that do not contain the loxP-flanked 
Ascl1 gene. After allowing the mice to drink the doxycycline water (1 mg/ml) ad libitum from 
gestation day (GD) 6, we collected maternal livers from both Ascl1+/+ and Ascl1-/- mice on GD9, 
11, 13, 15, and 18 (Fig. 3B). qRT-PCR showed, similar to C57BL6/J mice, the basal expression 
of hepatic Ascl1 in nonpregnant female mice, and confirmed the activation of the hepatic Ascl1 
mRNA expression in Ascl1+/+ mice and its successful ablation in Ascl1-/- mice on GD15 by 99.7% 
(Fig. 3C). Therefore, we were able to generate a doxycycline-induced global Ascl1 knockout 
mouse model and effectively delete Ascl1 during pregnancy. 
3.2.2 Global deletion of Ascl1 causes maternal liver abnormalities 
To determine if the loss of Ascl1 during pregnancy resulted in Ascl1-dependent phenotypes, 
we collected maternal livers and fetuses. After the Ascl1 ablation during pregnancy, we observed 
Ascl1-dependent abnormalities in the maternal liver. The Ascl1-/- mice showed a marked increase 
in liver-to-body weight ratio on gestation day (GD) 18 by 20% (Fig. 4A). Hematoxylin and eosin 
(H&E) staining showed aberrant staining patterns in the Ascl1-/- maternal livers, which had a layer 
of unstained substance and around the nuclei of hepatocytes during mid to late gestation (Fig. 4B). 
Furthermore, a proliferation marker Ki67 staining showed increased numbers of Ascl1-/- maternal 
hepatocytes undergoing cell cycle on GD13 by 277% and on GD15 by 204% (Fig. 4C-D). Finally, 






Figure 3. Doxycycline-induced global Ascl1 knockout mouse model. (A) The strategy of 
generating a global inducible Ascl1 knockout mouse model. In the global inducible Ascl1 knockout 
(Ascl1-/-) (Ascl1fl/fl;R26rtTA/rtTA;tetOCre/-) mice, the Rosa26 promoter element (R26) ubiquitously 
expresses the reverse tetracycline-controlled transactivator (rtTA). rtTA becomes activated by 
binding with doxycycline and turns on the tetracycline-responsive promoter element (tetO) to 
express Cre recombinase. Cre recombinase excises out the loxP-flanked Ascl1, resulting in the 
deletion of Ascl1 in the whole body except in the brain and testis. In the control mice (Ascl1+/+) 
(Ascl1+/+;R26rtTA/rtTA;tetOCre/-), the Ascl1 lacks the loxP sites and, therefore, remains intact after 
doxycycline treatment. (B) Doxycycline treatment timeline. The presence of a copulation plug 
(plug +ve) was designated as gestation day (GD) 1. Doxycycline was administered in drinking 
water (1 mg/ml) for both Ascl1+/+ and Ascl1-/- mice from GD6 until maternal samples were 
collected on GD9, 11, 13, 15, and 18. (C) Ascl1 mRNA expression in the maternal liver. Total 
RNA was isolated from livers of nonpregnant (NP) and gestation day 15 Ascl1+/+ and Ascl1-/- mice. 
Hepatic Ascl1 mRNA levels were measured using quantitative real-time polymerase chain reaction 
(qRT-PCR) and expressed as the mean fold changes relative to NP controls (± s.d.; n = 3 for each 
group). *, P < 0.05, between Ascl1+/+ and Ascl1-/- mice. Albumin mRNA levels were used as 












GD18 (Fig. 4E). Although maternal liver plays an essential role in the growth of the fetus, maternal 
liver abnormalities resulted from hepatic Ascl1 deletion did not affect the fetal weight and number 
(Fig. 4F-G). Taken together, we revealed that Ascl1 modulates the structure, cell cycle, and lipid 
metabolism of maternal hepatocytes. 
3.2.3 Global deletion of Ascl1 causes alterations in sera 
To determine functional alterations in the maternal body resulted from deleting Ascl1, we 
collected nonpregnant and maternal serums from Ascl1+/+ and Ascl1-/- mice and performed serum 
analysis. We observed changes in the liver function such as decreased levels of blood urea nitrogen, 
albumin, globulin, and total protein; lipid metabolism such as increased levels of free fatty acids; 
and placental secretion such as alkaline phosphatase (Fig. 5, Table 6). These data show that the 
deletion of maternal Ascl1 during pregnancy causes dysfunctions in the liver, placenta, and lipid 




















Figure 4. Global Ascl1 ablation phenotypes. (A-E) Maternal liver changes. Maternal livers were 
collected and weighed from Ascl1+/+ and Ascl1-/- mice (described in Fig. 3). (A) The maternal liver-
to-body weight ratios of Ascl1+/+ and Ascl1-/- mice are presented. Data are expressed as means ± 
s.d. (n = 5-9). **, P < 0.01, between Ascl1+/+ and Ascl1-/- mice. (B) Maternal liver histology. 
Maternal liver sections of Ascl1+/+ and Ascl1-/- mice were subjected to hematoxylin and eosin 
(H&E) staining. (C-D) Maternal hepatocyte proliferation. (C) Nonpregnant and maternal liver 
sections were subjected to Ki67 staining. Ki67-positive cells are stained dark brown in the nucleus. 
(D) Nuclear Ki67-positive hepatocytes were counted in five random fields of view (200X 
magnification) and the data are expressed as the means ± s.d. (n = 3-5). **, P < 0.01, between 
Ascl1+/+ and Ascl1-/- mice. (E) Maternal liver lipid deposition. Gestation day 18 maternal liver 
sections of Ascl1+/+ and Ascl1-/- mice were subjected to Oil Red O (ORO) staining. The lipid 
droplets are stained red. (F-G) Fetal outcome. Weight (F) and number (G) of pups born from 
Ascl1+/+ and Ascl1-/- dams are presented. Data are expressed as means ± s.d. (n = 5-9). Ascl1, 







































































Figure 5. Maternal serum biochemical profile. Maternal serum was collected from Ascl1+/+ 
and Ascl1-/- mice (described in Fig. 3). Maternal serum biochemical profiles from Ascl1+/+ and 
Ascl1-/- mice were analyzed by Eli Lilly and Company. Data are expressed as means ± s.d. (n = 
5). *, P < 0.05; **, P < 0.01; ***, P < 0.001, between Ascl1+/+ and Ascl1-/- mice. Ascl1, achaete-
scute homolog 1; BUN, blood urea nitrogen; Enz Creat, creatinine; ALP, alkaline phosphatase; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; Na, 
sodium; K, potassium; Cl, chloride; Ca, calcium; IP, inorganic phosphate; Glu, glucose; Chol, 
cholesterol; HDL Chol, high-density lipoprotein cholesterol; LDL Chol, low-density lipoprotein 
cholesterol; Trig, triglyceride; Phos Lipid, phospholipid; FFA, free fatty acid; Free Chol, free 





































Figure 5, continued. 
 
 
3.3 Cell-specific deletion of Ascl1 
3.3.1 Generation of cell-specific inducible Ascl1 knockout mouse model 
We then tested whether the deletion of Ascl1 specifically in the Ascl1-expressing cells causes 
similar maternal liver abnormalities, and thus complicates the overall pregnancy. To achieve both 
the deletion and labeling of Ascl1 in Ascl1-expressing cells, we generated the cell-Ascl1Cre/- 
(Ascl1Cre/fl;R26EYFP/EYFP) mouse line (Fig. 6A). In this inducible Ascl1 knockout mouse line, Ascl1-
expressing cells express Cre recombinase fused with tamoxifen-activated mutant estrogen ligand-
binding domain (ERT2) (CreERT2) and, with the administration of tamoxifen, remove the floxed 
Ascl1 gene while at the same time delete the transcriptional Stop cassette, which activates the 
expression of enhanced yellow fluorescent protein (EYFP). For control, we generated the cell-









strategy was such that both genotypes were present among the littermates. After injecting 
tamoxifen on gestation days (GD) 13 and 14, we collected maternal livers from both genotypes on 
GD15 and GD18 for analysis (Fig. 6B). qRT-PCR showed that the nonpregnant livers from both 
genotypes had a similar basal expression of Ascl1 mRNA, whereas the Ascl1Cre/- mouse livers had 
82.5% and 75.9% reduction in Ascl1 mRNA expression when compared with the controls on GD15 
and GD18, respectively (Fig. 6C). Thus, we were able to generate a cell-specific Ascl1 knockout 

















Figure 6. Tamoxifen-induced cell-specific Ascl1 knockout mouse model. (A) The strategy in 
generating cell-specific inducible Ascl1 knockout mouse model. In the cell-specific inducible 
Ascl1 knockout (cell-Ascl1Cre/-) (Ascl1Cre/fl;R26EYFP/EYFP) (R26-LoxP-Stop-LoxP-EYFP) mice, the 
Ascl1-expressing cells express CreERT2, which is a Cre recombinase fused with a mutant estrogen 
ligand-binding domain (ERT2) that is activated only by tamoxifen, but not naturally occurring 
estrogen. With the administration of tamoxifen, Cre-ERT2 fusion protein translocates into the 
nucleus and excises out the loxP-flanked Ascl1 and the transcriptional Stop cassette upstream of 
enhanced yellow fluorescent protein (EYFP). As a result, the Ascl1-expressing cells delete Ascl1 
and express EYFP. In the control mice (cell-Ascl1Cre/+) (Ascl1Crel+;R26EYFP/EYFP), Ascl1 lacks the 
loxP sites and, therefore, remains intact after tamoxifen treatment while still being labeled with 
EYFP. (B) Tamoxifen treatment timeline. The presence of a copulation plug (plug +ve) was 
designated as gestation day (GD) 1. Tamoxifen was intraperitoneally injected (i.p., 60 mg/kg) on 
GD13 and GD14 and maternal samples were collected on GD15 and GD18. (C) Ascl1 mRNA 
expression in the maternal liver. Total RNA was isolated from livers of nonpregnant (NP) and 
gestation day 15 cell-Ascl1Cre/+ and cell-Ascl1Cre/- mice. Hepatic Ascl1 mRNA levels were 
measured using quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as the 
mean fold changes relative to NP controls (± s.d.; n = 4-5). *, P < 0.05; ***, P < 0.001, between 
cell-Ascl1Cre/+ and cell-Ascl1Cre/- mice. 18S ribosomal RNA (rRNA) levels were used as 
























3.3.2 Deletion of Ascl1 in Ascl1-expressing cells causes maternal liver abnormalities 
We evaluated whether cell-specific deletion of Ascl1 resulted in similar maternal liver 
phenotypes as the global Ascl1 knockout. The lack of Ascl1 in cell-Ascl1Cre/- pregnant mice resulted 
in an increased liver-to-body weight ratio on GD15 and GD18 by 16% and 24%, respectively (Fig. 
7A). Hematoxylin and eosin staining on cell-Ascl1Cre/- maternal liver sections revealed 
abnormalities such as an overall reduction of eosin staining in the liver and a lack of staining 
around the nucleus of the hepatocyte on GD18 (Fig. 7B). Tracing the Ascl1-expressing cells by 
immunostaining both cell-Ascl1Cre/+ and cell-Ascl1Cre/- maternal livers showed a similar number 
and random distribution of YFP+ cells (Ascl1-expressing cells) (Fig. 7C). Cell-Ascl1Cre/- mice also 
had 15% larger placental weight on GD18 (Fig. 7D) but had similar fetal weight on both GD15 
and GD18 (Fig. 7E). Thus, we were able to successfully generate a cell-specific Ascl1 knockout 
mouse model and observe similar maternal hepatic abnormalities as the Ascl1 global knockout. 
Most importantly, using this model, we demonstrated that Ascl1 absence does not result in the 
reduction of maternal hepatocyte number or hepatocyte death. 
3.3.3 Deletion of Ascl1 in Ascl1-expressing cells causes alterations in maternal hepatic gene 
profile 
To investigate the Ascl1 target genes in Ascl1-expressing cells, we isolated total RNA from both 
cell-Ascl1Cre/+ and cell-Ascl1Cre/- mice on gestation day (GD) 15 and performed the RNA-
sequencing (RNA-seq) analysis. Using the Ingenuity Pathway Analysis (IPA), we detected 362 
genes up/downregulated by at least two-fold with an FDR value less than 0.05 in cell-Ascl1Cre/- 
maternal livers when compared with the controls (Fig. 8A). IPA displayed the top enriched 
canonical pathways affected by the Ascl1 ablation (Fig. 8B). In cell-Ascl1Cre/- maternal livers, 





















Figure 7. Cell-specific Ascl1 ablation phenotypes. (A-C) Maternal liver changes. Maternal livers 
were collected and weighed from cell-Ascl1Cre/+ and cell-Ascl1Cre/- mice (described in Fig. 6). (A) 
The maternal liver-to-body weight ratios of cell-Ascl1Cre/+ and cell-Ascl1Cre/- mice are presented. 
Data are expressed as means ± s.d. (n = 5-9). **, P < 0.01, between cell-Ascl1Cre/+ and cell-
Ascl1Cre/- mice. (B) Maternal liver histology. Maternal liver sections of cell-Ascl1Cre/+ and cell-
Ascl1Cre/- mice were subjected to hematoxylin and eosin (H&E) staining. (C) Cell lineage tracing. 
Maternal liver sections on gestation day 18 were subjected to green fluorescent protein (GFP) 
staining. GFP-positive cells are stained dark brown. (D-E) Pregnancy outcome. Placenta and 
fetuses were collected and weighed from cell-Ascl1Cre/+ and cell-Ascl1Cre/- mice. (D) Placental 
weight and (E) the number of pups born from cell-Ascl1Cre/+ and cell-Ascl1Cre/- dams are presented. 




























as coagulation and metabolism were downregulated. We documented the full lists of canonical 
pathways, p-values, z-scores, and the associated genes affected by Ascl1 deletion. Furthermore, 
IPA associated the differentially expressed genes targeted by Ascl1 to network categories grouped 
together based on known diseases and functions such as cell cycle, lipid metabolism, and 
development (Table 7). We documented the categorized lists of the Ascl1-associated networks. 
Therefore, Ascl1 has a wide range of effects in molecular networks and pathways of the maternal 
liver that deviates from a normal pregnancy. 
3.4 Hepatocyte-specific deletion of Ascl1 
3.4.1 Generation of hepatocyte-specific inducible Ascl1 knockout mouse model 
The previous data showed that deletion of Ascl1 in Ascl1-expressing cells caused overt maternal 
liver and placental phenotypes; nevertheless, we further examined whether deletion of Ascl1 
specifically in the liver resulted in similar pregnancy outcomes, as tamoxifen is associated with 
developmental abnormalities of the fetus, spontaneous abortions, pregnancy terminations, and 
stillbirths (179). To delete Ascl1 specifically in the maternal hepatocytes, we generated 
Ascl1fl/fl;R26EYFP/EYFP (R26-LoxP-Stop-LoxP-EYFP) mouse line (Fig. 9A). In this inducible and 
hepatocyte-specific Ascl1 knockout mouse line (hep-Ascl1-/-), injecting AAV8-TBG-Cre, where 
adeno-associated virus (AAV) 8 specifically targets the liver and thyroxine-binding globulin 
promoter (TBG) expresses only in the hepatocytes, into the animal causes the removal of the floxed 
Ascl1 gene and the Stop cassette upstream of enhanced yellow fluorescent protein (EYFP). 
Therefore, the maternal hepatocytes ablate Ascl1 while, at the same time, being labeled with EYFP. 
For control (Ascl1fl/fl), we introduced a null gene using the AAV8 virus to the same mouse model, 
















Figure 8. Differentially expressed genes and canonical pathways affected by Ascl1 ablation 
in Ascl1-expressing cells. Maternal livers were collected from cell-Ascl1Cre/+ and cell-Ascl1Cre/- 
mice (described in Fig. 6). Total RNA was isolated from livers of cell-Ascl1Cre/+ and cell-Ascl1Cre/- 
mice on gestation day (GD) 15 using RNeasy Plus Mini Kit. The isolated RNA was sent to the 
Center for Medical Genomics Core (Indiana University School of Medicine) for RNA-sequencing. 
(A) Differentially expressed genes are presented by the volcano plot. Red, significantly up- or 
downregulated genes; black, green, and blue are non-significant genes. The differentially 
expressed genes with at least two-fold and p-value less than 0.05 were analyzed using the Ingenuity 
Pathway Analysis (IPA). (B) Top enriched canonical pathways targeted by Ascl1 are presented. 


























After injecting AAV8 virus on gestation day (GD) 8, we collected maternal organs from both 
genotypes on GD15 and GD18 for analysis (Fig. 9B). By qRT-PCR, we confirmed the successful 
knockout of hepatic Ascl1 by AAV8-TBG-Cre on GD15 by 96.9% and GD18 by 99.7% in the 
hep-Ascl1-/- mice when compared with the control mice (Fig. 9C). Therefore, we successfully 
generated a hepatocyte-specific conditional Ascl1 knockout mouse model. 
3.4.2 Hepatocyte-specific Ascl1 knockout results in maternal liver abnormalities 
Among the most apparent Ascl1 null phenotypes were increases of liver-to-body weight 
ratios on GD15 by 9% and on GD18 by 14% (Fig. 10A-B). By hematoxylin and eosin staining, 
similar to the cell-Ascl1Crel- mice using tamoxifen, we observed reduced staining patterns in the 
hep-Ascl1-/- maternal livers (Fig. 10C). By immunostaining with the cell proliferation marker Ki67, 
we found an increased number of Ki67+ hepatocytes in the maternal liver on GD18 by 114% when 
compared with the controls (Fig. 10D-E); however, we were unable to find hepatocytes 
undergoing mitosis. β-Catenin staining showed hypertrophy of maternal hepatocytes by 20% in 
the hep-Ascl1-/- mice (Fig. 10F-G). Thus, hep-Ascl1-/- maternal livers respond to pregnancy by 

















Figure 9. Virus-induced hepatocyte-specific Ascl1 knockout mouse model. (A) The strategy 
of generating hepatocyte-specific inducible Ascl1 knockout mouse model. In the hepatocyte-
specific inducible Ascl1 knockout (hep-Ascl1-/-) (Ascl1fl/fl;R26EYFP/EYFP) (R26-LoxP-Stop-LoxP-
EYFP) mice, adeno-associated virus 8 (AAV8)-thyroxine-binding globulin promoter (TBG)-Cre 
recombinase (AAV8-TBG-Cre) is injected. AAV8 specifically targets the liver and injects the 
vector that contains Cre recombinase driven by the TBG promoter, which is expressed only in 
hepatocytes. Only the hepatocytes express Cre recombinase, which excises out the loxP-flanked 
Ascl1 and the Stop cassette upstream of enhanced yellow fluorescent protein (EYFP), which 
results in the Rosa26 promoter element (R26) driving EYFP expression. Thus, the hepatocytes 
result in Ascl1 ablation and EYFP expression. In the control mice (Ascl1fl/fl), a virus with a null 
gene is introduced (AAV8-TBG-Null), and, therefore, retains the Ascl1 gene without being 
labeled with EYFP. (B) Virus treatment timeline. The presence of a copulation plug was 
designated as gestation day (GD) 1. AAV8-TBG-Cre or AAV8-TBG-Null was administered by 
tail vein injection (1x1012 genomic copies per mouse) to Ascl1fl/fl;R26EYFP/EYFP mice on gestation 
day (GD) 8 to generate hep-Ascl1-/- and Ascl1fl/fl, respectively. Samples were collected on GD15 
and GD18. (C) Ascl1 mRNA expression in the maternal liver. Total RNA was isolated from 
livers of nonpregnant (NP) and pregnant (GD15 and GD18) Ascl1fl/fl and hep-Ascl1-/- mice. 
Hepatic Ascl1 mRNA levels were measured using quantitative real-time polymerase chain 
reaction (qRT-PCR) and expressed as the mean fold changes relative to NP controls (± s.d.; n = 
4-5). ***, P < 0.001, between Ascl1fl/fl and hep-Ascl1-/- mice. 18S ribosomal RNA (rRNA) levels 














































Figure 10. Hepatocyte-specific Ascl1 ablation phenotypes. Maternal livers were collected and 
weighed from Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). (A) Morphology of the Ascl1fl/fl 
and hep-Ascl1-/- mice livers on gestation day (GD) 18. (B) The maternal liver-to-body weight ratios 
of Ascl1fl/fl and hep-Ascl1-/- mice are presented. Data are expressed as means ± s.d. (n = 4-6). *, P 
< 0.05; **, P < 0.01, between Ascl1fl/fl and hep-Ascl1-/- mice. (C) Maternal liver histology. Maternal 
liver sections of Ascl1fl/fl and hep-Ascl1-/- mice were subjected to hematoxylin and eosin (H&E) 
staining. (D-E) Maternal hepatocyte proliferation. (D) Maternal liver sections of Ascl1fl/fl and hep-
Ascl1-/- mice on GD18 were subjected to Ki67 staining. Ki67-positive cells are stained dark brown 
in the nucleus. (E) The nuclear Ki67-positive hepatocytes were counted in five random fields of 
view (200X magnification) and the data are expressed as the means ± s.d. (n = 3-6). ***, P < 0.001, 
between Ascl1fl/fl and hep-Ascl1-/- mice. (F-G) Maternal hepatocyte density. (F) Maternal liver 
sections of Ascl1fl/fl and hep-Ascl1-/- mice on GD18 were subjected to β-Catenin staining. β-Catenin 
stains the cell membrane dark brown. (G) The maternal hepatocytes were counted (200X 
magnification) and the data are expressed as the means ± s.d. (n = 7 for each group). ***, P < 































3.4.3 Hepatocyte-specific Ascl1 knockout causes alterations in maternal hepatic gene 
profile 
To determine the Ascl1 target genes in the maternal liver, we isolated total RNA from both 




Seq) analysis. Using the IPA, we observed 1,274 genes differentially expressed by at least two-
fold with an FDR value less than 0.05 in hep-Ascl1-/- maternal livers when compared with the 
controls. IPA summarized the top canonical pathways affected by hepatic Ascl1 ablation (Fig. 11). 
In hep-Ascl1-/- maternal livers, signaling pathways affected include downregulation of melatonin, 
nicotine, and dopamine degradations and upregulation of amyotrophic lateral sclerosis (ALS), 
pancreatic cancer, and interferon signaling. We documented the complete lists of canonical 
pathways, with p-values, z-scores, and associated genes. In addition, IPA analyzed and assigned 
the Ascl1 target genes to network categories of diseases and functions such as metabolisms of 
carbohydrate, nucleic acid, amino acid, disruptions in the cell cycle, and disorders of cellular 
function and development in the auditory and skin (Table 8). We documented the complete lists 
of networks and the associated genes. Hence, the ablation of maternal hepatic Ascl1 during 
pregnancy results in a wide range of gene expression changes. 
3.4.4 Hepatocyte-specific Ascl1 knockout changes hepatocyte identity 
CD133 (also referred to as PROM1) and epithelial cell adhesion molecule (EpCAM) are 
hepatocyte stem/progenitor cell markers that are also expressed in cancer stem cells (180). By 
RNA sequencing (RNA-Seq), we observed that Ascl1 deficiency affected the expression of hepatic 
CD133 mRNA on gestation day (GD) 15. In situ hybridization on GD18 showed comparable 
CD133 mRNA signals in both genotypes; however, while the CD133 mRNA remained in the 
hepatocyte nucleus in the Ascl1fl/fl hepatocytes, CD133 mRNA in the hep-Ascl1-/- hepatocytes 
showed the presence in both the nucleus and cytosol (Fig. 12A). qRT-PCR showed that the hep-
Ascl1-/- mice increased the expression of CD133 mRNA in the maternal liver on GD15 by 3.37-
folds and GD18 by 12.43-folds (Fig. 12B). In addition, we observed that the expression of hepatic 




decreased its expression on GD15 by 73% (Fig. 12C). Therefore, the ablation of Ascl1 influences 
the phenotypes of the hepatocytes by means of CD133 and EpCAM expression during pregnancy. 
3.4.5 Hepatocyte-specific Ascl1 knockout results in activation of Igf2 
Another surprising gene activated by removing Ascl1 in the maternal liver was the insulin-
like growth factor 2 (Igf2). Igf2 is an essential growth factor for fetal development but down-
regulated in adult tissues (181). In situ hybridization on GD 18 livers showed abundant Igf2 mRNA 
in hep-Ascl1-/- mice (Fig. 13A). qRT-PCR showed a 350-fold increase in the Igf2 mRNA level on 
GD18 (Fig. 13B). To determine which promoters of Igf2 are activated, we performed qRT-PCR 
to analyze promoter-specific Igf2 transcripts and observed that activity of the promoter (P) 0, a 
placenta-specific Igf2 promoter, was silent due to the loss of Ascl1 whereas fetal-specific P1, P2, 
and P3 promoters were activated on GD15 and GD18 (Fig. 13C). By qRT-PCR, we did not observe 
any differential expression of zinc finger protein 568 (Zfp568), which is known to silence the 
placental promoter of Igf2 in the placenta (Fig. 13D). This suggests that Zfp568 may not be 
involved in the regulation of P0 in maternal hepatocytes. Together, we found that the deletion of 
Ascl1 in maternal hepatocytes results in the activation of hepatic Igf2 via P1, 2, and 3. 
 




























Figure 11. Differentially expressed genes and canonical pathways affected by hepatocyte-
specific deletion of Ascl1 in the maternal liver. Maternal livers were collected and weighed from 
Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). Total RNA was isolated from livers of hep-
Ascl1-/- and Ascl1fl/fl mice on gestation day (GD) 15 using RNeasy Plus Mini Kit. The isolated 
RNA was sent to the Center for Medical Genomics Core (Indiana University School of Medicine) 
for RNA-sequencing. (A) Differentially expressed genes are presented by the volcano plot. Red, 
significantly up- or downregulated genes; black, green, and blue are non-significant genes. The 
differentially expressed genes with at least two-fold and p-value less than 0.05 were analyzed using 
the Ingenuity Pathway Analysis (IPA). (B) Top enriched canonical pathways targeted by hepatic 
Ascl1 are presented. Orange, upregulated; blue, downregulated. Ascl1, achaete-scute homolog 1; 

































Figure 12. Changes in maternal hepatocyte phenotypes after hepatic Ascl1 ablation. Maternal 
livers were collected from Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). (A) Hepatic CD133 
mRNA distribution in the maternal liver after hepatic Ascl1 deletion. Maternal liver sections of 
Ascl1fl/fl and hep-Ascl1-/- mice on gestation day (GD) 18 were subjected to CD133 in situ 
hybridization using RNAscope 2.5 HD Assay-BROWN kit. The CD133 mRNA is stained dark 
brown. (B-C) Total RNA was isolated from livers of nonpregnant (NP) and pregnant (GD15 and 
GD18) Ascl1fl/fl and hep-Ascl1-/- mice. Hepatic (B) CD133 and (C) EpCAM mRNA levels were 
measured using quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as the 
mean fold changes relative to NP controls (± s.d.; n = 4-5). *, P < 0.05; **, P < 0.01, between 
Ascl1fl/fl and hep-Ascl1-/- mice. 18S ribosomal RNA (rRNA) levels were used as endogenous 























Figure 13. Hepatic Igf2 activation after hepatic Ascl1 ablation. Maternal livers were collected 
from Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). (A) Hepatic Igf2 mRNA distribution in 
the maternal liver after hepatic Ascl1 deletion. Maternal liver sections of Ascl1fl/fl and hep-Ascl1-/- 
mice on gestation day (GD) 18 were subjected to Igf2 in situ hybridization using RNAscope 2.5 
HD Assay-BROWN kit. The Igf2 mRNA is stained dark brown. (B-D) Total RNA was isolated 
from livers of nonpregnant (NP) and pregnant (GD15 and GD18) Ascl1fl/fl and hep-Ascl1-/- mice. 
Hepatic (B) Igf2, (C) Igf2 promoter-specific transcript variants, and (D) Zfp568 mRNA levels were 
measured using quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as the 
mean fold changes relative to NP controls (± s.d.; n = 4-5). *, P < 0.05; **, P < 0.01; ***, P < 
0.001, between Ascl1fl/fl and hep-Ascl1-/- mice. 18S ribosomal RNA (rRNA) levels were used as 
endogenous controls. Ascl1, achaete-scute homolog 1; Igf2, insulin-like growth factor 2; Zfp568, 


































3.4.6 Hepatocyte-Specific Ascl1 knockout results in dysregulation of hepatic genes 
We next analyzed protein expression in hep-Ascl1-/- maternal liver. The maternal liver 
without Ascl1 activated hepatic insulin-like growth factor 2 (IGF2) on gestation day (GD) 18 (Fig. 
14A-B). However, we were unable to observe changes in the expression and activity of IGF2 
upstream regulator protein kinase B (AKT). Mammalian target of rapamycin (mTOR), which can 
be activated by AKT, decreased on GD15 by 44% whereas phosphorylated mTOR (p-mTOR) 
decreased on GD18 by 67%. Phosphorylated eukaryotic translation initiation factor 4E-binding 
protein 1 (P-4E-BP1) at T37/46, which can be activated by mTOR, increased on GD15 by 45% 
and on GD18 by 69%. Phosphorylated p70 ribosomal S6 kinase (p-p70S6K) at T389, which can 
also be activated by mTOR, did not show Ascl1-dependent change. We were unable to observe 
changes in the expression of total or phosphorylated extracellular signal-regulated kinase 1 and 2 
(ERK1/2), which play a role in cell proliferation and survival. Hep-Ascl1-/- liver had reduced 
expression of phosphorylated Janus kinase 2 (JAK2) at T1007/1008, which is involved in cell 
proliferation, on GD18 by 43%. CD133 increased on GD18 by 535%. Fatty acid binding protein 
4 (FABP4), which is involved in lipid transportation, increased on GD15 by 107% and on GD18 




by 212%. Taken together, we found that hepatic Ascl1 regulates the expression of a wide range of 
proteins in the maternal liver, which is associated with cell proliferation, growth, and metabolism. 
3.4.7 Hepatocyte-specific Ascl1 knockout causes alterations in sera 
We next examined the maternal liver function by collecting and analyzing the maternal 
sera of nonpregnant, GD15, and GD18 mice (Fig. 15) (Table 9). We observed changes in the liver 
function such as decreased levels of blood urea nitrogen, creatinine, creatine kinase, and total 
protein, and increased levels of alanine transaminase and aspartate aminotransferase. We also 
observed changes in lipid metabolism such as decreased levels of cholesterol, high- and low-
density cholesterol, and phospholipid, and increased levels of free fatty acid. These data show that 
hepatic Ascl1 absence causes liver and lipid metabolism dysfunctions, and results in abnormal 






























Figure 14. Hepatic protein expression after hepatic Ascl1 ablation. Maternal livers were 
collected from Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). (A) Maternal protein expression. 
Western blotting was performed on nonpregnant (NP) and pregnant maternal liver homogenates 
from Ascl1fl/fl and hep-Ascl1-/- mice using antibodies against the proteins listed. GAPDH protein 
levels were used as loading controls. (B) Quantification of the maternal protein expression. Hepatic 
maternal protein levels from Fig. 14A were measured using ImageJ and expressed as the mean 
fold changes relative to NP controls (± s.d.; n = 3 for each group). *, P < 0.05; **, P < 0.01; ***, 
P < 0.001, between Ascl1fl/fl and hep-Ascl1-/- mice. GD, gestation day. Ascl1, achaete-scute 
homolog 1; IGF2, insulin-like growth factor 2; AKT, total protein kinase B; ERK1/2, extracellular 
signal-regulated kinase 1/2; JAK2, Janus kinase 2; mTOR, mammalian target of rapamycin; 4E-
BP1, eukaryotic translation initiation factor 4E-binding protein 1; p70S6K, p70 ribosomal S6 
kinase; CD133, prominin-1; HGF, hepatocyte growth factor; FABP4, fatty acid binding protein 4; 































































Figure 15. Maternal serum biochemical profile. Maternal serum was collected from Ascl1fl/fl 
and hep-Ascl1-/- mice (described in Fig. 9). Maternal serum biochemical profile from Ascl1fl/fl and 
hep-Ascl1-/- mice was analyzed by Eli Lilly and Company. Data are expressed as means ± s.d. (n 
= 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001, between Ascl1fl/fl and hep-Ascl1-/- mice. Ascl1, 
achaete-scute homolog 1; BUN, blood urea nitrogen; Enz Creat, creatinine; ALT, alanine 
transaminase; AST, aspartate aminotransferase; CK, creatine kinase; Na, sodium; K, potassium; 
Cl, chloride; Ca, calcium; IP, inorganic phosphate; Chol, cholesterol; HDL Chol, high-density 
lipoprotein cholesterol; LDL Chol, low-density lipoprotein cholesterol; Trig, triglyceride; Phos 
Lipid, phospholipid; FFA, free fatty acid; Free Chol, free cholesterol; TP, total protein; Alb, 


































3.4.8 Hepatocyte-specific Ascl1 knockout causes hepatic fat accumulation 
To determine whether the maternal liver without Ascl1 accumulates fat, we performed the 
Oil Red O (ORO) staining. The results showed that the hep-Ascl1-/- maternal liver displayed a 4-
fold increase in lipid contents on GD15 when compared to the control mice (Fig. 16A). However, 
hepatic lipid content was not different between the two genotypes on GD18. qRT-PCR showed 
that the elongation of very long chain fatty acids protein 6 (Elovl6), which adds carbons to increase 
the length of fatty acids, in Ascl1fl/fl mice decreased on GD15 by 9% and on GD18 by 67% (Fig. 




in hep-Ascl1-/- mice decreased on GD15 by 82% (Fig. 16C). We observed no differential 
expression between genotype groups for fatty acid synthase (Fasn), which synthesizes long-chain 
saturated fatty acids, stearoyl-CoA desaturase (Scd1), which synthesizes oleic acid, and fat storage 
inducing transmembrane protein 1 (Fitm1), which involves in fat storage (Fig. 16D-F). Thus, these 
data suggest that Ascl1 regulates fat metabolism during pregnancy by modulating the expression 
of a subset of genes involved in lipid synthesis and breakdown. 
3.4.9 Hepatocyte-Specific Ascl1 knockout results in maternal pancreas abnormalities 
The maternal pancreas responds to pregnancy by the proliferation of maternal β-cells to 
increase insulin secretion and balance glucose homeostasis between the mother and the fetus (96). 
To determine whether the deletion of Ascl1 in the maternal hepatocytes caused changes to the 
liver-pancreas axis, we collected the maternal pancreas in Ascl1-/- mice on GD 18 and 19. We 
observed a 62% increase in the pancreas-to-body weight ratio in the Ascl1-/- mice when compared 
with the controls (Fig. 17A-B). We performed a glucose tolerance test by injecting 2 g of glucose 
per kg of body weight on GD18 and measured the blood glucose in 0, 15, 30, 60, 90, and 120 min 
after the administration. However, we were unable to observe differences in glucose tolerance 
between genotype groups (Fig. 17C). Furthermore, we stained the maternal pancreas on GD19 for 
insulin and found that the hep-Ascl1-/- pancreas had a reduction in insulin staining area by 50% in 
the ventral pancreas and 56% in the dorsal pancreas (Fig. 17D-E). By serum biochemistry analysis, 
we found that the serum glucose and insulin levels did not differ between genotypes on GD15 and 
GD18 (Fig. 17F-G). Both genotypes had similar Ki67 staining in both endocrine and exocrine 
cells (Fig. 17H). Therefore, in the absence of hepatic Ascl1, the maternal pancreas increases in 
















Figure 16. Hepatic lipid deposition and the expression of lipid-associated genes after hepatic 
Ascl1 ablation. Maternal liver and serum were collected from Ascl1fl/fl and hep-Ascl1-/- mice 
(described in Fig. 9). (A) Oil Red O (ORO) staining. Gestation day (GD) 15 livers from Ascl1fl/fl 
and hep-Ascl1-/- mice were subjected to ORO staining. The lipid droplets are stained red. (B-F) 
Hepatic lipid gene analysis. Total RNA was isolated from livers of nonpregnant (NP) and pregnant 
(GD15 and 18) Ascl1fl/fl and hep-Ascl1-/- mice. Hepatic (B) Elovl6, (C) Pnpla3, (D) Fasn, (E) Scd1, 
and (F) Fitm1 mRNA levels were measured using quantitative real-time polymerase chain reaction 
(qRT-PCR) and expressed as the mean fold changes relative to NP controls (± s.d.; n = 4-5). *, P 
< 0.05, between Ascl1fl/fl and hep-Ascl1-/- mice. 18S ribosomal RNA (rRNA) levels were used as 
endogenous controls. Ascl1, achaete-scute homolog 1; Elovl6, elongation of very long chain fatty 
acids protein 6; Pnpla3, patatin like phospholipase domain containing 3; Fasn, fatty acid synthase; 






















































Figure 17. Hepatocyte-specific Ascl1 ablation phenotypes in the maternal pancreas. The 
maternal pancreas was collected and weighed from Ascl1fl/fl and hep-Ascl1-/- mice (described in 
Fig. 9). (A) Morphology of the Ascl1fl/fl and hep-Ascl1-/- pancreas on gestation day (GD) 18. (B) 
The maternal pancreas-to-body weight ratios of Ascl1fl/fl and hep-Ascl1-/- mice are presented. Data 
are expressed as means ± s.d. (n = 4-5). **, P < 0.01, between Ascl1fl/fl and hep-Ascl1-/- mice. (C) 
Glucose tolerance test (GTT). Pregnant Ascl1fl/fl and hep-Ascl1-/- mice on GD18 were fasted for 6 
hrs and injected with glucose (2 g of glucose/kg of body weight) via intraperitoneally. Blood 
glucose levels were measured using a glucometer (OneTouch Ultra 2) before and 30 min after the 
glucose injection. (D-E) Pancreatic islet analysis. Maternal pancreatic sections of Ascl1fl/fl and hep-
Ascl1-/- mice on GD19 were subjected to β-Catenin staining. The quantification of percent area 
insulin staining in (D) ventral and (E) dorsal pancreas was performed by Eli Lilly and Company. 
Data are expressed as means ± s.d. (n = 3-5). *, P < 0.05, between Ascl1fl/fl and hep-Ascl1-/- mice. 
(F-G) Pancreatic function test. (F) Serum glucose was analyzed by Eli Lilly and Company and (G) 
serum insulin was analyzed by the Translation Core at the IU School of Medicine Center for 
Diabetes and Metabolic Diseases. Data are expressed as means ± s.d. (n = 3-6). (H) Maternal 
pancreatic proliferation. Maternal pancreatic sections of Ascl1fl/fl and hep-Ascl1-/- mice on GD18 
were subjected to Ki67 staining. Ki67-positive cells are stained dark brown in the nucleus. Ascl1, 

























3.4.10 Hepatocyte-Specific Ascl1 knockout results in abnormalities in maternal 
compartments 
The human maternal spleen enlarges approximately by 50% by the end of pregnancy (108). 
We have previously shown that the largest splenic growth takes place by the end of gestation in 
rats and during midgestation in mice due to an increase in the red pulp (177). The maternal spleens 




with the controls (Fig. 18A-B). By H&E staining, we were unable to identify overt structural 
phenotypes in the maternal spleens of hep-Ascl1-/- mice except that both the red and white pulps 
enlarged proportionally when compared with the controls (Fig. 18C). Interestingly, maternal 
kidney-to-body weight ratios in hep-Ascl1-/- mice increased on GD18 by 21% when compared with 
the controls (Fig. 18D). The results revealed that maternal liver crosstalks with other maternal 
organs via hepatic Ascl1. 
3.4.11 Hepatocyte-specific Ascl1 knockout results in placental abnormalities 
The placental weight in hep-Ascl1-/- mice had an increase of 26.9% on GD15 and had an 
increase of 33.0% on GD18 when compared with the controls (Fig. 19A). H&E staining showed 
that the placenta of hep-Ascl1-/- mice appeared enlarged with an expansion of both the junctional 
zone and the labyrinth zone (Fig. 19B). Periodic acid-Schiff (PAS) staining revealed similar 
glycogen staining in both genotypes (Fig. 19C). In situ hybridization showed similar staining in 
both genotypes for placental lactogen (PL)-I and II on GD15 and GD18, and PL-II on GD18 (Fig. 
19D). Serum biochemistry analysis revealed that, when compared with the controls, hep-Ascl1-/- 
mice had an increase of alkaline phosphatase (ALP) on GD15 and GD18 by 95% and 231%, 
respectively (Fig. 19E). We also analyzed the placental insulin-like growth factor 2 (IGF2) and its 
downstream proteins by western blotting (Fig. 19F). In the hep-Ascl1-/- placenta, IGF2 decreased 
by 32% on GD15 and the protein kinase B (AKT) increased in phosphorylation at S473 by 24% 
on GD18 but not on T308 during pregnancy. Interestingly, the hep-Ascl1-/- placenta on GD18 had 
decreased the activities of ERK1 by 80% and ERK2 by 76%. Furthermore, we did not observe 
significant changes in Janus kinase 2 (p-JAK2) activity and PL-II protein expression. Taken 
together, we demonstrated that the lack of Ascl1 in maternal hepatocytes leads to placental 

















Figure 18. Hepatocyte-specific Ascl1 ablation phenotypes in spleen and kidney. The maternal 
spleens and kidneys were collected and weighed from Ascl1fl/fl and hep-Ascl1-/- mice (described in 
Fig. 9). (A) Morphology of the Ascl1fl/fl and hep-Ascl1-/- mouse spleens on gestation day (GD) 18. 
(B) The maternal spleen-to-body weight ratios of Ascl1fl/fl and hep-Ascl1-/- mice are presented. 
Data are expressed as means ± s.d. (n = 4-10). *, P < 0.05, between Ascl1fl/fl and hep-Ascl1-/- mice. 
(C) Maternal splenic histology. Maternal splenic sections of Ascl1fl/fl and hep-Ascl1-/- mice on 
GD15 were subjected to hematoxylin and eosin (H&E) staining. (D) The maternal kidney-to-body 
weight ratios of Ascl1fl/fl and hep-Ascl1-/- mice are presented. Data are expressed as means ± s.d. 






























Figure 19. Hepatocyte-specific Ascl1 ablation phenotypes in the placenta. The maternal 
placenta was collected and weighed from Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). (A) 
Placental weights of Ascl1fl/fl and hep-Ascl1-/- mice are presented. Data are expressed as means ± 
s.d. (n = 4-9). *, P < 0.05; **, P < 0.01, between Ascl1fl/fl and hep-Ascl1-/- mice. (B-D) Maternal 
placental histology. Placental sections of Ascl1fl/fl and hep-Ascl1-/- mice on gestation day (GD) 15 
were subjected to (B) hematoxylin and eosin (H&E) and (C) periodic acid-Schiff (PAS) staining. 
The glycogen is stained red to purple. (D) Placental sections were also subjected to PL-I and PL-
II in situ hybridization staining using RNAscope 2.5 HD Assay-BROWN kit. The PL-I and PL-II 
mRNAs are stained dark brown. (E) Maternal serum analysis. Maternal serum was collected from 
Ascl1fl/fl and hep-Ascl1-/- mice (described in Fig. 9). Maternal serum alkaline phosphatase (ALP) 
from Ascl1fl/fl and hep-Ascl1-/- mice was analyzed by Eli Lilly and Company. (F) Placental protein 
expression. Western blotting was performed on GD15 and GD18 placental homogenates from 
Ascl1fl/fl and hep-Ascl1-/- mice using antibodies against the proteins listed. GAPDH protein levels 
were used as loading controls. (G) Quantification of the placental protein expression. Placental 
protein levels from Fig. 19F were measured using ImageJ and expressed as the mean fold changes 
relative to GD15 controls (± s.d.; n = 3 for each group). *, P < 0.05, between Ascl1fl/fl and hep-
Ascl1-/- mice. Ascl1, achaete-scute homolog 1; IGF2, insulin-like growth factor; ERK1/2, 
extracellular signal-regulated kinase 1/2; JAK2, Janus kinase 2; PL-II, placental lactogen II; 



































































3.4.12 Hepatocyte-specific Ascl1 knockout results in fetal growth abnormalities 
There were no differences in fetal weight and number between hep-Ascl1-/- and control 
mice on GD15 and GD18 (Fig. 20A-B). However, the bodyweight of pups born from hep-Ascl1-/- 
mice was heavier, when compared with the controls, on week 1 by 9%, 2 by 5%, and 5 by 5% after 
weaning for males and weeks 1 by 10% and 2 by 5% after weaning for females (Fig. 20C-D). The 
body weight changes of the pups born from hep-Ascl1-/- mice, when compared with the controls, 
increased on week 1 by 16% but decreased on week 2 by 41% in males and increased on weeks 1 
by 32% and 5 by 43% but decreased on week 2 by 35% and 3 by 38% in females (Fig. 20E-F). 
We also tested the blood glucose on the pups born from both genotypes but observed no differences 
in both males and females (Fig. 20G). Therefore, the ablation of maternal hepatic Ascl1 during 
pregnancy affects postnatal growth. 
3.4.13 Hepatocyte-Specific Ascl1 knockout results in changes in subpopulations of cecal 
microbiota 
We submitted cecal samples of both genotypes to Zymo Research Corporation (Irvine, CA) 
for sequencing analysis of 16s rRNA on gestation day (GD) 18. We observed changes in several 
subpopulations of cecal microbiota. Pseudobutyrivibrio-Roseburia intestinalis, Helicobacter 
hepaticus, Clostridiales vadinBB60 were present greater in the control cecal samples whereas 
Desulfovibrio oxamicus-vulgaris, Candidatus, Lactobacillus johnsonii, Eubacterium, and 
Bacteroides acidifaciens were more present in the hep-Ascl1-/- cecal samples (Fig. 21A). Notably, 
Pseudobutyrivibrio-Roseburia intestinalis was absent in the hep-Ascl1-/- cecal whereas 
Desulfovibrio oxamicus-vulgaris was absent in the control cecal. By qRT-PCR, we observed that 




100% GD18 due to the Ascl1 deficiency in maternal hepatocytes (Fig. 21B). Therefore, we 












































Figure 20. Hepatocyte-specific Ascl1 ablation phenotypes in the fetus and postnatal growth. 
Fetuses and weaned pups were collected and weighed from Ascl1fl/fl and hep-Ascl1-/- dams 
(described in Fig. 9). Fetal weight (A) and numbers (B) were recorded. (C-F) Postnatal pups were 
weighed after weaning. (G) Fetal glucose measurement. Fetal blood glucose was measured using 
a glucometer (OneTouch Ultra 2) 5 weeks after weaning. (± SEM; n = 13-31). *, P < 0.05; **, P 
< 0.01; ***, P < 0.001, between pups born from Ascl1fl/fl and hep-Ascl1-/- dams. Ascl1, achaete-

































Figure 21. Hepatocyte-specific Ascl1 ablation phenotypes in maternal cecal microbiota. The 
maternal cecal samples were collected from Ascl1fl/fl and hep-Ascl1-/- mice on gestation day (GD) 
18 (described in Fig. 9). (A) DNA was isolated from maternal cecal microbiota of Ascl1fl/fl and 
hep-Ascl1-/- mice on GD18 using the PureLink Microbiome DNA Purification Kit. Maternal cecal 
microbiota changes with P < 0.05 analyzed by Zymo Research Corporation. (B) Total RNA was 
isolated from livers of nonpregnant (NP) and pregnant (GD15 and GD18) Ascl1fl/fl and hep-Ascl1-
/- mice. Hepatic hepcidin antimicrobial peptide 2 (Hamp2) mRNA levels were measured using 
quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as the mean fold 
changes relative to nonpregnant (NP) controls (± s.d.; n = 3-4). **, P < 0.01; ***, P < 0.001, 
between Ascl1fl/fl and hep-Ascl1-/- mice. 18S ribosomal RNA (rRNA) levels were used as 











The liver maintains its size proportional to body weight under homeostasis (28). Many 
studies revealed the mechanisms of liver growth under injury and stress (1). The maternal liver is 
unique in that it increases in size and weight to accommodate the increased metabolic needs of the 
developing placenta and fetus (27). However, the current knowledge of maternal liver growth is 
lacking. Here, we identified achaete-scute homolog 1 (Ascl1), a proneural gene that is quiescent 
under homeostasis in the liver, highly activated in maternal hepatocytes during mid to late 
gestation. By establishing three distinct in vivo Ascl1 knockout mouse models, we demonstrated 
that hepatic Ascl1 affects the hepatocyte size and identity, numerous hepatic gene expressions, and 
many signaling pathways. Furthermore, hepatic Ascl1 influences multiple nonreproductive 
maternal organs as well as the placenta and fetus, which further illustrates the importance of this 
gene. Therefore, by elucidating the function of Ascl1 in the maternal liver, we may partially fill in 
the knowledge gap of the mechanisms behind the maternal liver adaptations, and help clarify the 
cause and develop novel therapies on pregnancy-related liver diseases. 
4.2 Mouse model 
We observed that the maternal hepatocytes activate and increase the expression of Ascl1 in 
most of the hepatocytes starting from midgestation until the end of pregnancy. Traditional 
knockout mouse studies cannot be applied to Ascl1 because pups born with Ascl1 deficiency die 
at birth due to respiratory and eating problems. To study the function of Ascl1 in adults and 
especially during pregnancy, we generated three independent inducible mouse lines that delete 




virus, respectively (130). Confirmed by quantitative real-time polymerase chain reaction (qRT-
PCR), all mouse models effectively deleted Ascl1 in the maternal liver.  
To delete Ascl1 globally during pregnancy, we generated the Ascl1-/- 
(Ascl1fl/fl;R26rtTA/rtTA;tetOCre/-) mouse model and administered doxycycline before the activation of 
hepatic Ascl1. Doxycycline is a derivative of tetracycline, an antibiotic categorized as a class D 
drug, that is effective against various infectious diseases in adult and pregnant women such as 
Lyme disease, anthrax, cholera, and malaria by inhibiting bacterial protein synthesis (182). 
Additionally, unlike tetracycline, prior research revealed no evidence of doxycycline causing 
adverse effects such as teratogenicity or hepatotoxicity (183, 184). The use of the doxycycline-
induced global knockout mouse model is prevalent in studying the function of a gene in various 
tissues and organs during development, adult, and pregnancy (185-188). By administrating 
doxycycline during pregnancy as described in other studies, we were able to successfully delete 
Ascl1 and analyze Ascl1-dependent phenotypes in the maternal liver and fetal outcomes (185, 186). 
However, we were unable to continue the study due to the reduced fetal numbers and weights, and 
the inability for the females to become pregnant. As a result, we used two different mouse models 
to delete Ascl1 in a cell-specific and hepatocyte-specific manner. 
To delete Ascl1 and trace the Ascl1-expressing cells during pregnancy, we generated the 
cell-Ascl1-/- (Ascl1Cre/fl;R26EYFP/EYFP) mouse model and administered tamoxifen before the peak 
activation of hepatic Ascl1. Tamoxifen is a nonsteroidal selective estrogen receptor modulator that 
has both estrogen antagonist and agonist effect in breast cancer cells and other tissues, respectively 
(189). Prior studies thoroughly investigated the use of tamoxifen to treat breast cancer; however, 
its use during pregnancy has adverse effects on the mother, placenta, and the fetus due to its tissue-




administration, tamoxifen may stabilize and increase the number of estrogen receptors, inhibit the 
secretion of placental hormones, and result in fetal toxicity and abortions (190-192). Nevertheless, 
differed from other published studies, we identified the optimal dose and volume of tamoxifen to 
minimize the deleterious effects in the embryo while at the same time ablating and labeling Ascl1 
in the maternal liver to identify and trace these Ascl1-expressing hepatic cells (193, 194). 
To delete Ascl1 in the maternal liver, we generated the hep-Ascl1-/- (Ascl1fl/fl;R26EYFP/EYFP) 
mouse model and administered AAV8 viruses before the activation of hepatic Ascl1. AAV8 and 
other AAV vectors are tissue and receptor-specific and can deliver recombinant DNA effectively 
as a form of gene therapy; however, since the introduced recombinant DNA not being able to 
integrate into the host genome, its expression dilutes over time due to cell division and turnover 
rate (195). Introduction of AAV vectors, which have a clearance time in the blood of 2 days, may 
develop a T-cell response, albeit lower than other viruses such as adenovirus, is not clearly 
understood (196, 197). Here, we used hepatocyte-specific AAV vector, AAV8, and hepatocyte-
specific promoter thyroxine-binding globulin promoter (TBG) at a dosage similar to previously 
published studies to induce the deletion of hepatic Ascl1 while using a null AAV8 virus as a control 
to offset any immunological response (198-200).  
4.3 Maternal liver and other organ growth 
One of the most noticeable physical phenotypes after deleting Ascl1 was the enlarged 
maternal livers. All three Ascl1 knockout animal models, global, cell-specific, and hepatocyte-
specific, manifested in the maternal liver-to-body weight increase. Two possibilities may 
contribute to the enlargement of the maternal liver: hepatic hyperplasia and hypertrophy. In a 
neural stem cell, sustained expression of Ascl1 results in cell cycle exit and differentiation (127). 




mid to late gestation, suggesting that the maternal hepatocytes are undergoing proliferation; 
however, we were unable to detect maternal hepatocytes in mitotic phase. Ki67 is present during 
G1, S, G2, and M phases, and does not indicate whether the cell completes cytokinesis. Additional 
candidates for liver growth by hyperplasia are hepatocyte growth factor (HGF) and insulin-like 
growth factor 2 (IGF2), in which we observed the increased expressions after deleting hepatic 
Ascl1. HGF is a potent hepatocyte mitogen, an essential growth factor for the development of 
multiple organs during embryogenesis, facilitates liver and other organ repairs after injury, and 
activates anti-apoptotic and anti-inflammatory signals (201). During liver growth and repair, 
sinusoidal cells and Kupffer cells produce HGF, which promotes hepatocyte cell cycle and protects 
from organ failure (201, 202). Another vital gene for liver growth is IGF2. IGF2 production not 
only occurs in the placenta but also in fetal organs such as the pancreas and liver (203, 204). IGF2 
binds to multiple variants of the insulin receptors during embryogenesis to induce metabolism, 
proliferation, differentiation, and anti-apoptosis (205). The increased concentration of serum IGF2 
directs increased growth rate and weights in the heart, kidney, and liver (206). Therefore, increased 
HGF and IGF2 may explain the enlarged maternal liver and other nonreproductive organs, such as 
the pancreas, spleen, and kidney, which we perceived after hepatic Ascl1 deletion. Taken together, 
hepatic Ascl1 may downregulate HGF, IGF2, and thereby cell proliferation to prevent abnormal 
organ overgrowth. However, our cell-specific lineage-tracing model did not demonstrate 
differences in GFP-positive hepatocytes, suggesting that deleting Ascl1 in the Ascl1-expressing 
hepatocytes does not result in cell proliferation. The other mode of liver enlargement is hepatic 
hypertrophy. Ascl1 ablation resulted in maternal hepatocytes increasing their cell size and 
decreasing their cell density during late gestation by 20% and, if we assume that there was no 




gestation day (GD) 18 by 14%. The difference in percentage may be due to the cellular contents, 
especially fat deposition, in the Ascl1 knockout hepatocytes. 
4.4 Maternal hepatocyte identity 
We also identified that the hepatic Ascl1 controls the maternal hepatocyte identity by 
affecting the expression of CD133, EpCAM, and albumin. Hepatic CD133 and EpCAM result in 
the “stemness” of the liver (207). CD133 localizes in the plasma membrane and, while its function 
is unknown, is a marker for cancer stem cells (208). Not only does CD133 express in various 
tumors such as prostate, colon, and ovary, liver cancer stem cells also express CD133 that results 
in proliferation and reduced expression of mature hepatocyte markers (209-212). We discovered 
that the expression of hepatic CD133 increased in Ascl1 knockout livers during pregnancy. On the 
other hand, CD133 expression is dynamically changed in pregnant livers, where the previous study 
illustrates that reduced levels of CD133 results in loss of tumor incidence (213). EpCAM is a 
transmembrane glycoprotein with various functions such as cell adhesion, proliferation, 
differentiation, and migration (214). During development, hepatoblasts and ductal plate cells 
express EpCAM whereas mature hepatocytes lack its expression (215). Furthermore, in addition 
to CD133, EpCAM is also a surface marker for liver cancer stem cells (213). We observed that the 
lack of hepatic Ascl1 results in maintenance of the EpCAM expression whereas its expression 
reduces in normal maternal livers. Albumin, constituting around half of the plasma proteins and 
2/3 of the plasma oncotic pressure, is a globular transport protein produced by the hepatocytes 
(216). Not only does albumin transport cholesterol, nitric oxide, fatty acids, and metals, it also 
interacts with drugs, antibiotics, and reactive species (217-219). The deletion of hepatic Ascl1 
resulted in lower levels of serum albumin. Low serum albumin associated with liver damage, such 




fat metabolism by binding to fatty acids in the blood; therefore, low levels of serum albumin may 
result in increased concentrations of lipids in the blood (219). Thus, Ascl1 expression in maternal 
liver may have a protective role against possible liver damage and formation of liver cancer cells, 
and proper productions and concentrations of albumin and lipids. 
4.5 Fatty liver 
In Ascl1 knockout maternal livers, we observed the abnormally reduced staining of eosin in 
the cytoplasm, which may be due to the abundant deposition of fat droplets detected by Oil Red O 
staining. This phenotype is similar to an acute fatty liver of pregnancy (AFLP), a maternal liver 
disease during pregnancy where current information is lacking (33). Accumulation of fat or 
triglyceride in the liver can damage the organ that can result in abnormal liver function and even 
cirrhosis, liver cancer, and mortality (222, 223). In this study, we presented evidences that Ascl1 
governs maternal liver health and fat by serum biochemistry such as alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), blood nitrogen urea (BUN), creatinine, creatine kinase 
(CK), cholesterol, including high- and low-density lipoprotein (HDL) cholesterols, and 
triglyceride. Additionally, we presented data on significantly up- and down-regulating genes and 
pathways associated with hepatosteatosis such as Elovl6, Pnpla3, fatty acid binding protein 4 
(FABP4), IGF2, Janus kinase 2 (JAK2), and mammalian target of rapamycin (mTOR). We also 
determined that hepatic Ascl1 does not regulate selective genes and pathways associated with lipid 
metabolisms such as fatty acid synthase (Fasn), stearoyl-CoA desaturase 1 (Scd1), fat storage 
inducing transmembrane protein 1 (Fitm1), extracellular signal-regulated kinase 1/2 (ERK1/2), 
and protein kinase B (AKT).  
The liver has high concentrations of both ALT and AST, and, therefore, their secretion into 




damage due to hepatitis, drugs, and fatty liver (224, 225). Interestingly, low serum calcium levels 
correlate with high levels of serum AST (226). Since an increase in serum ALT and AST levels 
mark steatohepatitis, without hepatic Ascl1, the maternal liver amasses fat, resulting in liver injury 
and ALT and AST release (227, 228). 
Elevated levels of serum CK reflects striated skeletal muscle damages and muscle-associated 
diseases (229, 230) On the other hand, low levels of serum CK associates with alcoholic liver 
disease due to reduced muscle mass (231, 232). As we also observed decreased levels of serum 
CK in the hepatic Ascl1 knockout mice, it will be also interesting to see whether fatty livers caused 
by the absence of Ascl1 result in muscle reduction.  
Urea and creatinine, which are metabolic products from liver and muscle, respectively, are 
an indication of kidney function (233, 234). Increased BUN levels may be due to inappropriate 
activation of the renin-angiotensin-aldosterone system and increased reabsorption of urea (233). 
BUN levels also increase due to diets with high protein, bleeding of the gastrointestinal tract, 
infection, and drugs (234). Furthermore, increased creatinine levels may be due to acute kidney 
injury or hemoconcentration (235). Nevertheless, after hepatic Ascl1 deletion, we observed both 
serum BUN and creatinine decrease. Decrease in BUN and creatinine production may be attributed 
to dysfunction of the liver such as parenchymal liver disease for reduced BUN production and 
alcoholic liver disease for reduced creatinine production (234, 236). This indicates that hepatic 
Ascl1 protects the maternal liver from impaired hepatic metabolic activity and injury. 
Elovl6 is an enzyme in lipogenesis that elongates saturated and monounsaturated fatty acids. 
Elovl6 activation modulates hepatic inflammation, oxidative stress, fibrosis, and steatosis (237, 
238). We detected that the Elovl6 expression in Ascl1 knockout maternal livers did not change 




in decreased lipid accumulation in the liver (239). Furthermore, in hepatocellular carcinoma 
(HCC), the absence of Elovl6 causes decreased proliferation, AKT activation, and growth (240). 
Thus, Ascl1 may downregulate Elvol6 to ameliorate lipid deposition in maternal hepatocytes. 
Pnpla3 hydrolyze triglycerides in hepatic stellate cells and hepatocytes (241). The loss-of-
function of Pnpla3 results in the accumulation and retention of hepatic triglycerides and many 
liver diseases such as fibrosis and steatosis. We found that ablation of hepatic Ascl1 results in the 
inability to activate Pnpla3 in maternal livers, and, therefore, may inhibit the gene’s lipase activity. 
FABP4 is a lipid-binding chaperone expressed in adipocyte and macrophages that plays an 
important role in insulin resistance and type 2 diabetes (242-244). Although the predominant 
hepatic form is fatty acid binding protein 1 (FABP1), we observed an increased level of hepatic 
FABP4 expression after the deletion of hepatic Ascl1 (245). Since elevated hepatic FABP4 
expression associates with hepatic steatosis, we conjecture that hepatic Ascl1 protects the liver 
from fat accumulation by downregulating FABP4. 
We analyzed lipid profiles in the Ascl1 knockout mice such as cholesterol, HDL cholesterol, 
LDL cholesterol, triglyceride, phospholipid, and FFA. The liver metabolizes, synthesizes, and 
transports lipids, which are essential in controlling cellular functions and homeostasis (246). 
Generally, lipid contents in the blood decrease depending on the cause and progression of the liver 
disease. For example, alcoholic and nonalcoholic cirrhotic livers result in lower concentrations of 
blood cholesterol, HDL and LDL cholesterols, and triglyceride levels whereas HCV-induced 
hepatic steatosis results in lower levels of blood lipids but not triglyceride (247-249). We found 
decreased levels of cholesterol, HDL and LDL cholesterols, and phospholipids while FFA levels 
increased in the absence of hepatic Ascl1 in maternal serum. While increased levels of serum FFA 




to the blood triglyceride levels (250, 251). Increased serum FFA levels also cause insulin resistance; 
however, blood insulin and glucose levels, in addition to glucose tolerance test, of the Ascl1 
knockout animals did not differ from the controls (252, 253). It will be interesting to see whether 
Ascl1 null hepatocytes exposed to high levels of FFA result in FFA-induced oxidative stress and 
inflammation (254). Taken together, the deletion of hepatic Ascl1 during pregnancy results in the 
imbalance of lipid metabolism and presents similar phenotypes as hepatic steatosis. 
IGF2 is not only a potent mitogen for organ growth, but also its overexpression results in 
hepatic steatosis by activating AKT and increasing serum cholesterol and hepatic lipid droplets, 
including free cholesterol, and obesity (255, 256). However, although we observed activation of 
hepatic IGF2, there was a disconnection in the signaling pathway since we were unable to detect 
AKT activation. Therefore, hepatic Ascl1 may downregulate IGF2 to control maternal liver growth 
and, potentially, hepatic fat deposition. 
JAK2 is a signal traducer activated by growth hormones and regulates many liver physiology 
(257). Expression levels of JAK2 increase in genes associated with fibrosis due to myofibroblastic 
hepatic stellate cells activation while deletion of JAK2 is lethal during fetal development (258, 
259). The phenotypes of hepatocyte-specific deletion of JAK2 are smaller body, fatty liver, where 
the hepatic triglycerides increased significantly without inhibiting secretion or increasing fatty acid 
synthesis and increased serum free fatty acid (260). We observed similar properties where the 
absence of hepatic Ascl1 also resulted in reduced level of JAK2, increased liver fat content and 
serum free fatty acid. Thus, hepatic Ascl1 appears to have a partially similar role as hepatic JAK2 
in lipid metabolism. 
mTOR is a signaling pathway that involves various metabolism and physiology in the body 




inhibiting lipophagy and activates lipogenesis. However, hepatic Ascl1 resulted in reduced 
activation of mTOR while maintaining similar levels of p70S6K. Furthermore, we observed 
another disconnection to the mTOR signaling pathway, 4E-BP1. Ascl1 knockout resulted in 
increased activation of 4E-BP1, another downstream effector of mTOR, and may have a protective 
role against fatty liver since the ablation of 4E-BP1 results in obesity (262). Therefore, there is a 
disconnection between mTOR, p70S6K, and 4E-BP1 due to an unknown mechanism with the 
absence of hepatic Ascl1 expression. 
4.6 Pancreatic function test 
During pregnancy, the preexisting maternal β-cells proliferates and increases insulin 
production to maintain maternal blood glucose levels (95, 96). We found that, after hepatic Ascl1 
deletion, the maternal pancreas increased in size and weight, which may be due to the increased 
expression of IGF2. Furthermore, IGF2 overexpression causes β-cell dysfunction and damage by 
cell dedifferentiation and endoplasmic reticulum stress, resulting in type 2 diabetic phenotypes 
including increased blood insulin and glucose, and abnormal insulin and glucose tolerance tests 
(263, 264). Additionally, hepatic Elovl6 upregulation associates with insulin resistance and hepatic 
ERK1/2 promotes insulin resistance, weight gain, and obesity (240, 265, 266). Finally, circulating 
hepatic HGF may bind to the pancreas and act in metabolic homeostasis by stimulating mitosis 
and regulating insulin production of the β-cells, and maintain blood glucose levels (267). 
Nevertheless, we were unable to observe any differences in pancreatic cell proliferation, blood 
glucose or insulin levels, and glucose tolerance test. Since the pancreatic islet sizes were similar 
even without hepatic Ascl1, we postulate that the increase in the organ size may be due to an 




4.7 Ascl1-associated canonical pathway 
RNA sequencing analysis revealed that hepatic Ascl1 regulates multiple canonical pathways 
in the liver. We received two different significantly up- or down-regulated canonical pathways 
using two independent mouse lines: cell-specific and hepatocyte-specific. The difference may stem 
from the timing of the Ascl1 deletion and the type of cells involved. In cell-specific Ascl1 deletion, 
many of the death signaling pathways and cell cycle regulations were upregulated whereas the 
prothrombin activation pathway was downregulated. On the other hand, in hepatocyte-specific 
Ascl1 deletion, many of neurotransmitter signaling molecule degradation pathways were 
downregulated while amyotrophic lateral sclerosis signaling, the degeneration of muscle neurons, 
and immune response were upregulated. Both the afferent and efferent neurons innervate the liver 
and, while the hepatic vagus nerve has been studied recently, to our knowledge, there is no current 
knowledge in the degradation pathways presented in our studies (268). Thus, hepatic Ascl1 
regulates the neurotransmitters in an unknown mechanism. 
4.8 Microbiota dysfunction 
Maternal microbiota plays an essential role in inoculating the baby during birth, which may 
affect the health of the baby (70, 73, 74). We observed the dysbiosis of the microbiota in the 
maternal cecal samples such as Pseudobutyrivibrio-Roseburia intestinalis, Helicobacter hepaticus, 
Clostridiales vadinBB60, Bacteroides acidifaciens, Eubacterium, Lactobacillus johnsonii, 
Candidatus, and Desulfovibrio oxamicus-vulgaris. 
Roseburia intestinalis is one of the most abundant bacteria in the body and helps in 
protecting colonic mucosa against inflammatory bowel disease (IBD) (269). Helicobacter 
hepaticus infection results in hepatic oxidative stress and may play a role in liver cancer (270). 




insulin levels (271). The genus Eubacterium produces butyrate, which helps in the proliferation of 
colonic epithelial cells (272). Lactobacillus johnsonii is a lactic acid bacterium and functions as a 
probiotic as well as produces antibiotic against certain bacterial species (273). Candidatus 
designates bacteria that are unable to grow in culture plates (274). Desulfovibrio oxamicus-vulgaris 
uses nitrate and reduces it to ammonium, and incompletely oxidizes lactate, alcohol, pyruvate, and 
more (275).  
One of the genes that may be the cause of dysbiosis is Hamp2. Hamp2 is an antimicrobial 
peptide that expresses primarily in the liver and plays an important role in the immune response 
against bacterial pathogens (276, 277). In the absence of hepatic Ascl1, hepatic Hamp2 expression 
decreased markedly, which may have caused changes in the populations of these cecal bacterial 
strains. Although the function of these bacteria needs to be more elucidated, it will be of interest 
to see whether the imbalance of microbiome may result in future health problems for the pups born 
from hepatic Ascl1-null dams. 
4.9 Pregnancy outcomes 
We postulate that activation of IGF2 in the absence of hepatic Ascl1 causes both the placental 
and postnatal growth. For the placenta, we analyzed the disrupted expression levels of IGF2, AKT, 
ERK1/2, serum alkaline phosphatases (ALP), and placental lactogen I (PL-I) and placental 
lactogen II (PL-II), which are hormones produced by the placenta during gestation, in the absence 
of hepatic Ascl1; however, JAK2 expression did not differ between genotypes. In addition, we 
measured the postnatal growth of the pups born from hepatic Ascl1 knockout dams and observed 
increased growth rate in both males and females. 
IGF2, an imprinted gene where only the paternal allele expresses and the maternal allele 




IGF2 is also necessary for the development and function of the trophoblast (280). We detected 
lower levels of placental IGF2 production in the hepatic Ascl1 knockout mice, which may be due 
to the compensation of the activation of IGF2 in the maternal liver. We also observed activation 
of placental AKT, which is downstream of the IGF2 signaling pathway, that was absent in the 
maternal liver without Ascl1. Thus, hepatic Ascl1 may regulate hepatic IGF2 production, which 
then downregulates placental IGF2 production. 
In homeostasis, ALP production occurs in the liver; however, during pregnancy, the placenta 
takes over the production and reaches its peak until the end of pregnancy (281). We observed an 
increased level of serum ALP in hepatic Ascl1 knockout pregnant mice, which may be due to liver, 
kidney, and pregnancy-related diseases (282). High levels of ALP may also associate with 
premature birth, placental insufficiency, and decreased birth weight; however, we were unable to 
observe any of these phenotypes in our studies (283, 284). Thus, hepatic Ascl1 ablation results in 
an increased size of the placenta in an unknown mechanism. 
PL-I production occurs in trophoblast giant cells in the placenta from gestation day (GD) 6 
until GD13 whereas PL-II production occurs from the same giant cells from GD10 until the end 
of pregnancy (285, 286). The concentration of the maternal serum PL-I correlates with litter size 
(287). We observed an increased placental size in hepatic-specific Ascl1 knockout mice; however, 
this increase did not affect the production or distribution of both placental lactogens. Thus, hepatic 
Ascl1 does not affect the endocrine production of PL-I and PL-II in the placenta. 
ERK1/2 plays an important role in trophoblast differentiation while a mutation in JAK2 
results in pregnancy complications (288, 289). Inhibition of ERK1/2 constrains trophoblast 




ERK1/2 while JAK2 expression levels did not differ from the control placenta. Therefore, hepatic 
Ascl1 may control the maturation of trophoblast but not JAK2 expression in the placenta. 
The deletion of Ascl1 in the maternal liver also results in increased growth in pups after 
weaning. Whereas the deletion of IGF2 results in much smaller fetuses, an increase in IGF2 
expression causes increase fetal overgrowth (278, 290). Furthermore, IGF2 is sex-dependent 
where overexpression of fetal IGF2 during pregnancy shows increased weight of fetus, stomach, 
intestine, liver, and pancreas in males and increased fetal stomach weight in females (291). 
Although we did not observe fetal overgrowth before parturition, we hypothesize that the 
overproduction of IGF2 during pregnancy may have caused the increased body weight and growth 
rate of the pups born from Ascl1 knockout dams. 
4.10 Summary of the findings 
The maternal liver adapts to pregnancy to accommodate the growing placenta and fetus. 
However, how the maternal liver adjusts metabolically and physiologically to pregnancy is largely 
unknown. We found that Ascl1 is the most activated gene in the maternal liver starting from 
midgestation. Hepatic Ascl1 in vivo lineage tracing and knockout mice showed the wide 
distribution of Ascl1-positive hepatocytes in the maternal liver and hepatic lipid accumulation in 
the absence of hepatic Ascl1 (Fig. 21). In addition, hepatic Ascl1 mediates crosstalk between the 
maternal liver with other maternal organs, such as the pancreas, spleen, and kidney, microbiome, 
and placenta, which may influence postnatal growth possibly via IGF2 or HGF. Hence, hepatic 
Ascl1 plays an important role in regulating other maternal organ adaptations and normal placental 







Figure 22. Summary of hepatic Ascl1 functions during pregnancy. Ascl1, achaete-scute 
homolog 1; IGF2, insulin-like growth factor 2; Hamp2, hepcidin antimicrobial peptide 2; HGF, 
hepatocyte growth factor. 
4.11 Future directions of the study 
The major follow up study is to determine (1) human relevance and (2) mechanism of hepatic 
Ascl1 in maternal organs and pregnancy outcomes. Additionally, we planned to overexpress 
hepatic IGF2 using a virus in normal pregnant mice to attempt to duplicate the hepatic Ascl1 
knockout phenotypes. However, after numerous attempts, we were unable to overexpress hepatic 
IGF2. Therefore, we plan to use a different viral construct. If our hypothesis regarding organ 
growth due to increased expression of IGF2 is correct, the maternal organs, placenta, and fetus 




the phenotypes of Ascl1 deletion in the liver, then an unknown factor or pathway may be the cause 
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